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Two of the.major functions of the kidney are to maintain the osmolality and volume 
of body fluids despite wide variations in daily intake of salt and water. The control of 
body fluid osmolality is important for normal cell function in all body tissues and control 
of body fluid volume is necessary for normal function of the cardiovascular system. The 
kidney accomplishes these tasks by regulating the excretion of water and salt. Although 
water and salt reabsorption occurs along the entire nephron, the final adjustments in the 
composition and volume of the urine are made in the collecting duct. The cortical 
collecting duct (CCD) is of special interest since it is primarily controlled by the 
hormones aldosterone and arginine vasopressin (A VP). 
Aldosterone is a steroid hormone that stimulates salt reabsorption in the collecting 
duct by a mechanism involving increased protein synthesis and activation of sodium 
channels [1, 2]. AVP is a protein hormone that stimulates salt and water reabsorption in 
the collecting duct by activation of multiple signalling pathways and second messengers 
that lead to insertion of sodium channels and water channels into the plasma membrane 
[3, 4]. While the aldosterone effect may take an hour to occur, the AVP effect occurs 
within minutes, making A VP critical in maintaining constant plasma volume and 
osmolality [2, 5]. Inhibitors of A VP-stimulated salt and water reabsorption in the rat 
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CCD include alpha-2 ( a2) adrenergic agonists [ 6-8], atrial natriuretic peptide [9], 
prostaglandin E2 [10], bradykinin [11], dopamine [12], peptide YY [13], and the 
neurotransmitter neuropeptide Y [14]. Imidazoline compounds also cause diuresis and 
natriuresis in the rat, but by a A VP-independent mechanism [15, 16]. 
The signalling pathways and second messengers indicated in A VP-stimulated 
transport and its inhibition are complex and do not function independently of each other. 
Some of the interactions between receptors and second messengers in the principal cell of 
the collecting duct are shown in diagram 1. The classic explanation of A VP-mediated salt 
and water reabsorption in the collecting duct consists of V 2 receptor stimulation by A VP 
which activates adenylyl cyclase (AC) leading to an increase in adenosine 3',5'-cyclic 
monophosphate ( cAMP) within the cell [ 17, 18]. This action is inhibited by stimulation 
of a2 receptors which inhibit AC and decrease cAMP accumulation within the cell [19, 
20]. Some a2 agonists are also imidazolines and can bind to an additional site separate 
from a2 receptors, called imidazoline (I) receptors [21, 22]. Binding of imidazoline agents 
to I receptors in the rat induces diuresis and natriuresis that has been linked to the cAMP 
pathway [16, 23] and to the production of diacylglycerol [24]. More recently, Y 
receptors have been implicated in salt and water resorption in the kidney. Neuropeptide 
Y (NPY) and peptide YY (PYY), members of the family of pancreatic polypeptides, both 
bind to Y receptors which have also been found in the kidney [25]. NPY has been shown 
to inhibit A VP-stimulated water permeability in the CCD [26], while functional studies 
of PYY in the kidney have not yet been conducted. 
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Diagram 1. Schematic representation of some of the receptors and signalling 
systems and their interactions in a cell. Solid lines represent stimulation or 
activation and broken lines represent inhibition. A VP, arginine vasopressin; 
ANP, atrial natriuretic peptide; a.2, alpha-2 adrenergic receptor; PGE2, 
prostaglandin Ei; NPY, neuropeptide Y; PYY, peptide YY; I, imidazoline 
receptor; D, dopamine; c++, calcium; PLC, phospholipase C; PKA and PKC, 
protein kinase A and C, respectively; PL, phospholipid; PLA2, 
. phospholipase A2; AA, arachidonic acid; Gi, inhibitory G protein; Gs, 
stimulatory G protein; GC, guanylate cyclase; IP3, inositol 1,4,5-
trisphosphate; PIP2, phosphatidyl inositol 4,5-bisphosphate; DAG, 
diacylglycerol; BK, bradykinin. 
While binding of an a.2, I, or Y agonist to the receptor is known to cause a decrease in 
salt and water reabsorption in the kidney, the exact mechanisms of these actions are still 
unclear. The V2 receptor is coupled to a stimulatory G protein (Gs) that stimulates salt 
and water permeability by AC activation, cAMP generation, and PKA activation [27]. 
The a.2 receptors are coupled to pertussis toxin (PTX)-sensitive inhibitory G proteins 
(Gi) that inhibit AC activation and cAMP generation within the cell [19, 26, 28] (diagram 
3 
1 ). Additional evidence suggests, however, that other mechanisms independent of AC 
and cAMP inhibition are involved in the a.2 response. First, a.2 agonists inhibit A VP-
stimulated salt and water permeability even in the presence of constant intracellular levels 
of cAMP [29]. Second, prostaglandin and PKC inhibitors reverse ai-mediated inhibition 
in the inner medullary collecting duct (IMCD), and this occurs even in the presence of 
constant cAMP [30]. 
Binding of I receptor agonists, which also bind to a.2 receptors, increases salt and 
water excretion in the rat independent of AVP [16] and linked to multiple pathways. 
Two cAMP-mediated pathways have been indicated, one involving a PTX-sensitive G 
protein [28] and another that is PTX-insensitive [23]. Other effects of I receptor 
activation include PLC activation and generation of diacylglycerol and arachadonic acid 
[24] and stimulation of endogenous prostaglandin production [16]. Finally, Y receptor 
stimulation induces diuresis and natriuresis [14, 25, 26, 31, 32] and can cause inositol 
phosphate-dependent and independent calcium mobilization in some cell types that is 
attenuated by prostaglandin inhibitors [33-35]. 
1.2 Purpose of the Study 
The goal of this project is to identify the functional receptor-mediated mechanisms 
involved in the inhibition of A VP-stimulated salt and water permeability in the rat CCD. 
This will be accomplished using the isolated perfused tubule technique in which a single 
CCD segment is suspended between concentric pipettes in a bathing chamber on an 
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inverted microscope. Various receptor agonists and antagonists as well as specific signal 
pathway inhibitors will be added to the bathing solution. This technique allows for 
determination of the osmotic water permeability coefficient (Pr) and characterization of 
salt transport using electrophysiological recordings of transepithelial voltage CVt), 
transepithelial resistance (Rt), basolateral membrane voltage (V bt) and fractional resistance 
of the apical membrane (/Rap). 
The specific aims of this project are: 
1) Determine the involvement of calcium, prostaglandins, and protein kinase C in the 
signalling pathways used in the mechanism of alpha-2-mediated inhibition of AVP-
stimulated transport in the CCD. 
2) Determine the effect of the alpha-2 adrenergic agents oxymetazoline, ARC-239, and 
WB4101 on the alpha-2 mediated inhibition of A VP-stimulated transport in the CCD. 
3) Determine the effect of agmatine on A VP-stimulated transport in the CCD. 
4) Determine the effect of PYY on A VP-stimulated transport in the CCD. 
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Chapter II 
REVJEW OF LITERATIJRE 
The review of literature begins with a brief discussion on the mammalian nephron, 
with emphsis on the cortical collecting duct. The collecting duct is the final nephron 
segment where salt and water reabsorption can occur in the kidney. In addition, the 
collecting duct is under hormonal control, making it critical in the daily regulation of 
plasma osmolarity and blood pressure. The transporters and ion channels responsible for 
this regulation are discussed and include water channels, sodium channels, potassium 
channels, chloride channels, and sodium transporters. The specifics of hormonal control 
in the principal cell of the collecting duct is covered as well as some of the receptors 
known to reside there including vasopressin receptors, adrenergic receptors, imidazoline 
receptors, and Y receptors. Finally, some of the signalling pathways and second 
messengers involved in salt and water transport in the collecting duct are discussed, 
including G proteins, adenylyl cyclase and cAMP, protein kinase A, phosphotidyl-
inositol, protein kinase C, and prostaglandins. 
2.1 Mammalian Nephron 
The kidney produces urine through the processes of filtration, reabsorption, and 
secretion. Plasma is filtered at the glomerulus, water and solutes are reabsorbed, and 
selected solutes are secreted into the tubular lumen. The functional unit of the kidney is 
6 
the nephron. The nephron consists of the glomerular capsule, proximal tubule, loop of 
Henle, distal tubule, and collecting duct ( diagram 2). The collecting duct is subdivided 
into the cortical, outer medullary, and inner medullary collecting ducts, and each segment 
possesses distinct cell types and functions [36]. The ascending limb of the loop of Henle, 
distal_ convoluted tubule, and collecting duct are specialized with tightly regulated 
transport properties that allow the kidney to produce urine with a different composition 
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Diagram 2. The Mammalian Nephron. 
The proximal tubule reabsorbs about 67% of the filtrate produced by the glomerulus, 
which includes water, sodium, chloride, potassium, and other solutes. In addition, the 
proximal tubule reabsorbs all of the filtered glucose and amino acids. The loop of Henle 
reabsorbs about 25% of the filtered sodium, chloride, and potassium from the thick 
ascending limb and about 15% of the filtered water from the thin descending limb. The 
distal tubule reabsorbs approximately 5% of the filtered load and the collecting duct 
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reabsorbs the remaining 2-3%, resulting in net sodium reabsorption of more than 99% of 
the filtered load. Quantitatively, the amount of filtrate reabsorbed in the collecting duct is 
small, but since it is the last segment of the nephron to influence sodium and water 
excretion it is critical in the determination of plasma osmolarity and volume. 
2.2 Cortical Collecting Duct 
The cortical collecting duct (CCD) consists of two basic cell types. Intercalated cells 
are responsible for hydrogen and bicarbonate transport important in maintenance of acid-
base balance [38]. Principal cells reabsorb sodium and water, and secrete potassium, 
giving them a major role in the regulation of blood pressure [37]. These responses are 
hormonally controlled by A VP and the mineralocorticoid aldosterone. 
Both hormones stimulate sodium and potassium transport in the CCD and both have 
been shown to increase the amiloride-sensitive sodium conductance of the luminal 
membrane of the principal cell [39-42]. The increase in sodium permeability results from 
translocation of epithelial sodium channels from intracellular vesicles to the apical plasma 
membrane and/or the activation of cryptic channels already present in the membrane [5, 
43-45]. 
A VP also increases water permeability in the principal cell. Water channels 
( aquaporins) are present in cytoplasmic vesicles within the cell and upon A VP 
stimulation these vesicles are translocated to the apical membrane thereby increasing 
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water permeability [3, 46]. AVP initiates this effect by binding to specific receptors that 
are located on the basolateral membrane of the principal cell [47] (diagram 3). 





Diagram 3. In the principal cell of the cortical collecting duct, A VP binds to 
the V 2 receptor located on the basolateral membrane. This binding activates a 
stimulatory G protein (Gs) which then activates adenylyl cyclase (AC). AC 
catalyzes the formation of cAMP from ATP resulting in an increase in 
intracellular cAMP levels. The increase in cAMP leads to activation of other 
second messengers that ultimately induce the insertion of sodium and water 
channels, or aquaporins, into the apical membrane. 
2.3 Transporters and Ion Channels in the CCD 
Movement of solutes and water across epithelium occurs with the aid of epithelial 
transport proteins. These proteins are broadly catagorized as pumps, carriers, and 
channels. Pumps are active transporters, requiring energy from the hydrolysis of ATP to 
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move solute against a concentration gradient. Carriers are proteins that bind ions or 
specific substrates and move them across a membrane in a passive (no ATP required) or 
active (ATP required) manner. Carriers include cotransporters (symports) that carry two 
or more solutes in the same direction, or countertransporters (antiports) that move 
solutes in opposing directions. Channels are proteins that provide a pore allowing solute 
or water to passively diffuse across the membrane down a concentration gradient. The 
movement of solute involves active and passive processes while the movement of water is 
always passive. 
In addition to water channels and epithelial sodium channels introduced in the 
previous section, the principal cell of the CCD contains potassium channels, chloride 
channels, and several ion transporters that allow stringent regulation of water and 
electrolyte movement. The most prominent ion transporter present is the sodium-
potassium ATPase (Na/K-ATPase), which generates the electrochemical gradient that 
drives water and ion movement across cell membranes. Other sodium transporters that 
have been proposed in the principal cell include the sodium-chloride (NaCl) symport and 
sodium-hydrogen exchanger (NHE). 
2.3.1 Water Channels 
AVP stimulation results in the insertion of aquaporins (AQPs), intrinsic membrane 
proteins that function as water-selective channels, into the apical membrane of the 
principal cell. The AQP channels allow water to diffuse passively across the membrane. 
There are at least four mammalian AQPs characterized (AQPl - AQP4) and each has 
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multiple names. The first to be identified was CHIP28 (channel-forming integral protein 
of 28 kDa) and was later called AQP-CHIP or AQPl [48]. It is mercury-sensitive and 
found in two forms: a 28 kDa nonglycosylated form (CHIP28) and a 40-60 kDa 
glycosylated form (glyCHIP) [48]. AQPl is the major water channel of the erythrocyte 
membrane [ 48], and is also found in the apical and basolateral membranes of the proximal 
tubule and thin descending limb ofthe loop of Henle [49-52]. 
AQP2, also called AQP-CD or WCH-CD (water channel-collecting duct), is found 
exclusively in the renal collecting duct and is responsible for A VP-regulated water 
transport across collecting duct cells [4, 46, 53]. AQP2 is mercury-sensitive and found 
only in the apical membrane and intracellular vesicles [46, 54]. Numerous studies have 
shown that AQP2 is transported to the apical membrane in the presence of AVP, and 
removed in the absence of AVP by a process termed the "shuttle hypothesis" [4, 46, 53, 
55-59]. The mechanism of the shuttle hypothesis is still not fully understood, but 
evidence suggests that AQP2 housed in intracellular vesicles is targetted to the apical 
membrane with the aid of vesicle-associated membrane protein 1 (V AMPl) [60]. Vesicle-
associated membrane protein 2 (V AMP2), also known as synaptobrevin, is implicated in 
the fusion of the vesicle to the plasma membrane [61]. Finally, the microtubule-
associated protein dynein and the associated dynactin complex have been shown to play a 
role in vesicle trafficking to the membrane [ 62]. 
AQP3, also known as GLIP (glycerol-transporting integral protein) or BLIP 
(basolateral integral protein), is also found in renal collecting duct cells. Like AQP2, it is 
mercury-sensitive and permeable to water in the presence of AVP [63-65]. In contrast to 
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AQP2, AQP3 is confined to the basolateral membrane with no evidence of intracellular 
trafficking [66, 67] and is also permeable to urea and glycerol instead of being selective 
only for water [64, 68]. 
AQP4, also known as the mercury-insensitive water channel (MIWC), is the 
osmoreceptor found in the brain that senses the need for antidiuresis [69]. AQP4 is also 
found in the kidney inner medulla but not the cortical collecting duct [70]. Like AQP3, 
AQP4 is localized to the basolateral membrane but in contrast to AQP3, is not inhibited 
by mercury [71]. Also, unlike AQP2 and AQP3, water restriction does not increase 
AQP4 expression and it has been speculated that the AQP4 may provide a pathway for 
basolateral exit of water in the IMCD [70]. 
The general structure of the AQPs has been characterized by studies on the molecular 
structure of AQPl (diagram 4). It is a homotetramer containing four independent aqueous 
units [48, 72, 73]. Each monomer has six membrane-spanning a-helices which form a 
right-handed bundle around a central core [74, 75]. The six membrane-spanning regions 
are connected by five loops, three of which are extracellular (loops A, C, and E) and two 
that are cytosolic (loops Band D) [48, 76, 77]. The amino and carboxyl termini are both 
intracellular [ 46, 77]. 
The structure of AQP-2 is thus visualized to have an hourglass shape, and is referred 
to as the hourglass model [73]. Loops B and E are both hydrophobic, closely associated 
spacially, and share the same Asn-Pro-Ala motifs. This, along with the finding that 
mutations in either loop B or loop E greatly reduce permeability, indicate that this may 
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act as the central pore for the entry of water [73]. In addition, a cysteine residue at 




Diagram 4. Membrane topology of one aqueous unit of the AQP-2 water 
channel. 
2.3.2 Sodium Channels 
The sodium channels of the nephron fall into the class of epithelial sodium channels 
(ENaC) found in many tight, salt-reabsorbing epithelia. They are distinct from voltage-
gated sodium channels, and are responsible for passive movement of sodium across apical 
or outward-facing membranes as the first step in the process of transepithelial sodium 
transport [45]. The ENaC channels allow sodium to diffuse down its electrochemical 
gradient into cells, where it is then extruded by the Na/K-ATPase located on the 
basolateral side (discussed in section 2.3.4). These channels are defined functionally as 
components of the membrane that move sodium into the cell by electrodiffusion without 
coupling to other solute flow and without direct use of metabolic energy. They are 
further defined pharmacologically by their sensitivity to the diuretic amiloride and its 
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analogs [79-82]. These amiloride-blockable channels have been classified into three 
groups: 1) channels with high selectivity to sodium over potassium (PNJPK ~ 10), low 
conductance (-5 pS), and long open and closed times (0.5-5.0 s); 2) channels with 
moderate selectivity (PNPK = 3-4), high conductance (7-15 pS), and short open and 
closed times ($; 50 ms); 3) nonselective cation channels (PNJPK:::;; 50), with high (23-28 
pS) or low (~ 3 pS) conductances [83-85]. It is the highly selective, low conductance 
ENaC of the distal nephron that allows maintainance of total sodium balance [79, 86]. 
The ENaC from the distal nephron is composed of three homologous subunits: alpha 
(a-ENaC), beta (~-ENaC), and gamma (y-ENaC) which share 35% identity between them 
[87, 88] (diagram 5). All three subunits are glycosylated and each has two putative 
transmembrane domains (Ml and M2). Each subunit is a protein with a large hydrophilic 
loop (-50 kDa) between Ml and M2 in the extracellular space, a:nd short hydrophilic 
NH2 and COOH terminals (9 and 10 kDa) in the cytoplasm. [87-90]. The transmembrane 
segments are predicted to have an a-helical structure followed by a stretch of 
hydrophobic residues in a ~-sheet structure [87, 89]. The extracellular loop contains 
about 500 residues and evidence suggests that the amiloride binding site resides in this 




Diagram 5. Membrane topology of the epithelial sodium channel (ENaC) of 
the CCD. 
The three ENaC subunits are well polarized and targeted only to the apical membrane 
and intracellular pools [93]. The subunits are coexpressed equally in the apical membrane 
and all three must be present for full activity of the channel. Studies have shown that ~-
ENaC and y-ENaC subunits alone or together could not induce amiloride-sensitive 
currents. The a.-ENaC subunit alone or with either of the other two subunits induces 
only 2 to 10% of the maximal activity observed in the presence of all three subunits [93]. 
2.3.3 Potassium Channels 
Potassium channels are classified into two broad groups based on their functional and 
biophysical properties. There are the delayed or outward rectifiers that are activated by 
depolarization, and the inward rectifiers that include the classical . inward rectifying 
channel and the ATP-sensitive K channels [94]. The inward rectifiers are characterized 
by their ability to conduct K more readily into the cell than out of the cell and by a lack of 
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significant gating by voltage [95]. The classical inward rectifiers, also called the strong 
inward rectifiers, are found in excitable cells and function in the maintenance of the resting 
membrane potential and in regulating excitability. The ATP-sensitive K channels are 
weaker inward rectifiers than the classical and open and close in response to metabolic 
events [95, 96]. 
Potassium channels in the CCD serve three important functions. First, they maintain 
the lumen negative potential of the tubule cells, which is dependent on K conductances. 
The high intracellular concentration of K is generated by the basolateral Na/K-ATPase 
that extrudes Na from the cell in exchange for extracellular K and by the diffusion 
potential ofK across the basolateral membrane [97]. Second, they recycle K across the 
basolateral membrane as a supply for the Na/K-ATPase. This recycling mechanism 
provides K to the extracellular fluid and safeguards continued turnover of the A TPase 
during extracellular K fluctuations. Third, they play a key role in K secretion. 
Electrophysiological studies have defined pathways for passive movement of K across 
basolateral and apical membranes [39, 96]. 
Patch-clamp analysis has led to the identification of at least four distinct K channels 
in principal cells [95, 98-101], and there is stronge evidence that both apical and 
basolateral K channels contribute to K secretion. There are two classes of K channels in 
the apical membrane and two in the basolateral membrane. · In the apical membrane, the 
maxi-K channel is activated by depolarization, has a large conductance of <100 pS and a 
low open probability (P0 <0.0l) [97]. The apical low-conductance K channel is activated 
by low pH or PKA, has a conductance of about 30 pS and a high open probability 
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(P0>0.90) [97, 99]. This channel is ATP-regulated and thus often referred to as the KATP 
channel [95] or the ROMK channel [95, 102]. The ROMK channel is a member of the 
family of inwardly rectifying potassium (IRK) channels and their expression is regulated 
by aldosterone and K [102]. Several variants of the ROMK channel have been identified, 
with ROMKl and ROMK2 being found in the CCD, and consist of 2 membrane-
spanning regions (Ml and M2) making it distinct from voltage-gated or ligand-gated ion 
channels [95]. The basolateral K channel is activated by hyperpolarization, has a 
conductance of 28 pS and a variable open probability [97]. In addition, an intermediate 
conductance channel located on the basolateral membrane has been described with a 
conductance of 85 pS [101]. This K channel is inhibited by high cytosolic calcium 
concentrations as opposed to the large conductance channel of the luminal membrane 
which is activated by high calcium levels [103]. 
2.3.4 Chloride Channels 
Chloride (Cl) is the predominant anion in the glomerular filtrate and over 99% of Cl 
and Na are reabsorbed along the nephron. The pathways of renal chloride transport may 
be transcellular or paracellular and are often coupled to Na transport. They are also 
involved in a variety of renal functions, including water and solute reabsorption, urinary 
acidification, cell volume regulation, and endosomal acidification. While the paracellular 
route is passive, the transcellular route involves membrane channels. 
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The CCD contains principal cells, primarily responsible for Na and K transport, and 
two types of intercalated cells. Type A (a) intercalated cells contain a bicarbonate 
(HC03)/Cl exchanger and a chloride channel on the basolateral membrane and are 
primarily responsible for hydrogen secretion. The type B (~) intercalated cell contains a 
HC03/Cl exchanger and a chloride channel on the apical membrane, and a chloride channel 
on the basolateral membrane. Type B cells are primarily responsible for HC03 secretion 
[104]. Intracellular microelectrode and patch-clamp studies indicate that principal cells 
have very little, if any, apical Cl conductance while the basolateral membrane is highly 
conductive to Cl [105, 106]. 
The two most prominant Cl channels in the CCD include the CLC ( also known as 
the CIC, for chloride channel) and the CFTR ( cystic fibrosis transmembrane conductance 
regulator). The CLC chloride channels are a family of channels with 9 members identified 
to date [107, 108]. These channels are the CLC-1, CLC-2, CLC-3, CLC-4, CLC-5, CLC-
6, CLC-7, CLC-Ka/Kl, and CLC-Kb/K2. Although they differ in their biophysical 
properties, distribution, and cellular compartmentalization, all share common structural 
features. The CLC channels consist of 10 to 12 transmembrane regions with cytoplasmic 
amino and carboxyl domains [109]. While 8 of these channels have been identified in the 
kidney, only the CLC-K2 has been identified in the rat CCD [110]. 
The CFTR channel is a chloride channel found in the apical membrane of many 
epithelial cells, and mRNA for the channel is expressed in all nephron segments [111]. It 
is a cAMP-regulated protein that is defective in cystic fibrosis, but evidence suggests that 
it is also a regulator for other membrane conductances. CFTR is expressed in all cell 
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types of the mouse and rabbit CCD [112] where it inhibits the ENaC channel [113, 114] 
and modulates the activity of renal ROMK2 channels [115, 116]. 
The CFTR has a voltage dependent low-conductance (9 pS) for chloride and is a 
member of a family of ATP binding casettes (ABC). These membrane proteins are 
composed of two transmembrane domains, each with six membrane-spanning regions, and 
cytoplasmic amino an.fl carboxyl terminals. The CFTR also contains two intracellular 
nucleotide binding domains and a large regulatory domain [111]. 
2.3.5 Sodium-Potassium ATPase 
In renal tubular cells the Na/K ATPase is located exclusively on the basolateral 
membrane (see Diagram 11, page 55). The main function of this ATPase is to pump Na 
out of the cell and extracellular K into the cell using the energy from ATP hydrolysis. 
Although it may be considered an ion transporter (Na pump) or an enzyme (ATPase), 
both functions are achieved by this single protein complex. For each ATP molecule 
hydrolyzed, the Na/K-ATPase moves two K ions into the cell and three Na ions out of 
the cell. This unbalanced ion exchange causes the electrogenicity of the ATPase [117]. 
Molecular cloning has shown that the Na/K-ATPase is made up of two main subunits ( a 
and~) [118]. The a subunit consists of 10 transmembrane domains with cytoplasmic 
amino and carboxyl termini, and a long intracytoplasmic loop. The cytoplasmic domain 
contains binding sites for sodium and ATP and a phosphorylation site, and the 
extracellular domain contains binding sites for potassium and ouabain, and is therefore 
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considered to be the catalytic subunit [117]. The B subunit is smaller than the a, and 
contains a single transmembrane domain with several glycosylation sites. The B subunit 
assists in the folding of newly synthesized a subunits and stabilizes the a subunits 
within the plasma membrane [119]. Although the B subunit has no enzymatic or 
transport activity, its association with the a subunit is necessary for ATPase and pump 
activity [120]. 
2.3.6 Sodium Transporters: Na/Cl Symport and Na/H Exchanger 
The principal cell of the rat CCD contains sodium transporters in addition to the 
Na/K-ATPase discussed in the previous section. Experimental studies show the existence 
of sodium-chloride (Na/Cl) and sodium-hydrogen (Na/H) cotransport and exchange 
mechanisms, respectively. Evidence of a neutral Na/Cl cotransporter (symport) within 
the apical membrane comes from experiments using isolated rat CCDs in which certain 
hormones inhibit sodium transport without changing transepithelial voltage [9, 121]. In 
CCDs from deoxycorticosteroid (DOC)-treated rats, hydrochlorothiazide reduces sodium 
and chloride reabsorption without effecting transepithelial voltage, and amiloride 
decreases sodium reabsorption by only 50% [122]. DOC is converted to corticosterone 
and then to aldosterone by hydroxy lase enzymes in the adrenal cortex, thereby increasing 
Na channel activity and Na absorption. Hydrochlorothiazide is an inhibitor of NaCl 
transport and amiloride is a Na channel inhibitor. The finding that half of the net sodium 
absorption can be inhibited by thiazides and half can be inhibited by amiloride indicates 
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the rat CCD contains more than one mechanism of sodium entry. There is conflicting 
data on this point, as studies on principal cells of amiloride-treated rats produces no 
intracellular depolarization with the addition of ouabain [39]. Depolarization would have 
occurred if sodium were allowed across the apical membrane via another transporter. The 
actual location of this proposed CCD Na/Cl symport is unknown, and it is possible that 
it resides in cells that do not contain epithelial sodium channels. 
The principal cell of the rat CCD may also contain a neutral Na/H exchanger 
(antiport)[123]. There are four types of Na/H exchangers known to exist, designated 
NHE-1, NHE-2, NHE-3, and NHE-4 [124]. NHE-2 is found mostly in the proximal 
tubule and inner medullary collecting duct and NHE-3 is found in the proximal tubule and 
thick ascending limb of the rat kidney [125]. 1'UIE-4 is found in the rat inner medullary 
collecting duct [126]. The NHE-1 is expressed ubiquitously and is located on the 
basolateral membrane [127, 128]. 
The NHE-1 isoform, designated as the 'housekeeping' isoform, is inhibited by 
amiloride and the imidazoline agonist moxonidine [128]. It is important in intracellular 
pH and cell volume regulation and may play a role in essential hypertension [124, 129]. 
The NHE-1 exchanger is a membrane protein of 815 amino acids with 12 transmembrane 
domains and an amiloride binding site on the 4th membrane-spanning region [130]. There 
is a hydrophobic domain within NHE-1 thought to be responsible for the transport of 
sodium and hydrogen, and a hydrophilic domain within the cytoplasmic carboxyl 
terminus that is affected by protein kinases [ 13 0, 131]. There are several potential 
phosphorylation sites for PKC and PKA in the NHE-1 isoform and activation of PKC by 
21 
phorbol 12-myristate 13-acetate (PMA) augments the activity of NHE-1 [131, 132]. In 
the rat CCD, NHE-1 is responsible for regulation of cellular pH in the principal cell and is 
activated by PKC and inhibited by PKA [123]. 
2.4 Hormonal Control of Salt and Water Transport in the CCD 
Although salt and water transport occur in several places along the nephron, final 
regulation occurs in the collecting duct to insure that daily excretion or output is equal to 
dietary intake or input. This regulation is controlled by hormones in the CCD. The most 
prominent influences are made by A VP, mineralocorticoids, catecholamines, natriuretic 
peptides, and endothelin. The following review summerizes these hormones and their 
effects in the collecting duct with particular emphasis on effects within the rat CCD. 
2.4.1 Aldosterone 
Aldosterone increases the amiloride-sensitive sodium conductance of the apical 
membrane thereby increasing sodium reabsorption in the rat CCD [2, 39, 133]. 
Aldosterone increases sodium reabsorption in the principal cell of the CCD in two ways: 
first by activation of sodium channels located on the apical membrane and second by 
increasing the activity of the Na/K-ATPase on the basolateral membrane. These events 
also increase potassium secretion [134, 135]. Thus, sodium absorption is a two-step 
process involving the passive entry of sodium from the tubular lumen into the cell 
through apical sodium channels followed by active extrusion through the basolateral 
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Na/K-ATPase pump into the serosal compartment. While some control of sodium 
transport occurs at the basolateral step, most of the ion movement is controlled by the 
apical ENaC sodium channel [5]. 
The increase in sodium transport by aldosterone occurs slowly and requires gene 
expression and protein synthesis [2, 136, 137]. Aldosterone, a steroid hormone, enters 
the cell by diffusion and binds to cytoplasmic receptors which then migrate as a complex 
to the nucleus. There it binds to DNA and promotes the synthesis of mRNA and 
specific proteins [138]. The resulting transport response has been shown to be 
dependent on this synthesis since it can be prevented by inhibitors of protein synthesis 
and mRNA [138, 139]. The end result is an increase in the amiloride-sensitive sodium 
conductance of the apical membrane which allows sodium to enter the cell via its 
electrochemical potential gradient. 
The mechanism for the increased sodium permeability has been a topic of much 
debate. The current and most accepted theory is that ENaC channels (discussed in 
section 2.3 .2) exist in the apical membrane in both active and inactive states, and that 
aldosterone increases sodium transport by activating inactive or "cryptic" channels [ 42, 
43]. This activation may be associated with methylation of inactive channels [140]. 
2.4.2 l'asoJJressin 
Vasopressin (A VP) increases sodium reabsorption and water permeability in the 
principal cell of the CCD [141-143]. Using the isolated perfused tubule technique, 
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investigators have shown that AVP increases lumen-to-bath sodium transport and keeps 
it elevated for up to 5 hours [142]. In addition, AVP increases osmotic water 
permeability (Pr) in the rat CCD from zero to as high as 1000 µm/sec [144]. Using 
electrophysiological methods, A VP and non-hydrolyzable cAMP analogs have been 
shown to increase apical membrane sodium conductance [39, 40]. 
As with aldosterone, the increase in A VP-stimulated sodium transport is due to an 
increased activity of amiloride-sensitive ENaC channels (discussed in section 2.3.2) in the 
apical membrane [2, 11, 142, 145]. In contrast to aldosterone, these effects appear to be 
due to an increase in the number of ENaC channels in the apical membrane rather than 
activation of channels that are already present [3, 43, 146]. The additional ENaC 
channels are contained in vesicles located . in. the · cytoplasm and are transported to the 
apical membrane in the presence of AVP [147-149]. 
A VP induces formation of coated pits and insertion of intramembrane particles 
(IMP) into plasma membranes [143, 150-153] indicating that the ENaC channels enter the 
lipid bilayer via clathrin-mediated endocytosis [153]. While some of the IMPs are 
associated with insertion of sodium channels as previously mentioned, others are involved 
in water channel trafficking. A VP has been shown to induce water permeability in the 
CD via the relocation of AQPs (discussed section 2.3.1) from intracellular vesicles to the 
apical membrane [3, 150, 154, 155]. In addition, the removal of AVP results in the 
removal of these channel proteins from the membrane [152, 156]. Recent studies have 
suggested that the vesicle-targeting proteins synaptobrevin-2 and syntaxin-4 may play a 
role in this process [155]. 
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2.4.3 Epinephrine and Norepinephrine 
Epinephrine and norepinephrine are catecholamines that are released from the adrenal 
medulla and bind to adrenergic receptors (discussed in section 2.5.2). Biosynthesis of 
catecholamines occurs in the adrenal chroma:ffin cell by the following pathway, with 




l (tyrosine hydroxylase) 
Dopa 
l (amino acid decarboxylase) 
Dopre 
( dopamine ~-hydroxy lase) 
N orepinephrine 
l (phenylethanolamine N-methyltransferase) 
Epinephrine 
Epinephrine and norepinephrine are also neurotransmitters synthesized within and 
released from nerve cells. The adrenal medulla secretes more epinephrine than 
norepinephrine, while nervous tissue releases predominantly norepinephrine. Thus when 
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considering the effects of catecholamines on renal function it should be noted that 
epinephrine is the principal circulating adrenergic hormone. 
In the isolated perfused rat kidney, norepinephrine or epinephrine perfused at 
constant pressure increases sodium reabsorption and increases free water clearance [157]. 
Epinephrine and norepinephrine bind differentially to all classes of adrenergic receptors 
(alpha-I, alpha-2, beta-1, beta-2). Specifically, beta-2 receptors are more sensitive to 
epinephrine than norepinephrine, and are more sensitive to epinephrine than are the 
alpha- I receptors. Thus the net effect of infusion of epinephrine may involve summation 
of effects at various sites in the nephron [158]. In the isolated perfused rat CCD, alpha-I 
and alpha-2 receptors are present, with a predominance of the alpha-2 subtype [159]. 
Epinephrine and norepinephrine binding to the alpha-2 adrenergic receptor suppresses 
', 
intracellular cAMP stimulation by A VP [29, 160, 161]. 
2.4.4 Dopamine 
Dopamine is another catecholamine synthesized in neurons as a precurser to 
norepinephrine and epinephrine, however renal dopamine is also produced independently 
of nerve activity. Renal dopamine is synthesized in proximal tubule cells by the action of 
amino acid decarboxylase (AADC) on L-3,4-dihydroxyphenylalanine (L-DOPA) [162, 
163]. L-DOPA enters the cell via a sodium transporter in the apical membrane [164] and 
is decarboxylated to dopamine, which exits the cell apically or basolaterally [163]. The 
basolateral dopamine transporter is dependent on sodium and pH, and little is known 
about the apical transporter [165]. Dopamine regulates the activities of various renal 
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sodium transporters, including the Na/K-ATPase and Na/H exchanger, and promotes 
sodium excretion [ 166-169]. In contrast to epinephrine and norepinephrine, which cause 
natriuresis by activation of adrenergic receptors, dopamine binds to specific dopamine 
receptors [170]. There are at least five dopamine receptor subtypes which are divided 
into two main classes, the Di-like and the Drlike. The Di-like division includes the Di 
and D5 receptors and the Drlike division includes the D2, D3, and D4 receptors [170]. 
In the rat CCD, the Di and D4 receptors are expressed [171] and dopamine 
administration results in inhibition of A VP-stimulated sodium reabsorption and osmotic 
water permeability [168]. The natriuretic and diuretic effects in the CCD appear to be 
mediated by the D4 subtype [168, 171] and occur via the inhibition of cAMP 
accumulation [12, 172]. 
2.4.5 Serotonin 
In the proximal tubule, AADC converts L-5-hydroxytryptophan (L-5-HT) to 
serotonin (5-HT) [173-175]. In contrast to dopamine, which causes natriuresis and 
diuresis, renal serotonin promotes sodium and water reabsorption [163, 176]. There are 
at least 10 types of 5-HT receptors (5-HTiA, 5-HTrn, 5-HTic, 5-HTrn, 5-HTrn, 5-
HT2A 5-HT2B 5-HT3 5-HTip 5-HT4) which are divided into three major families (5-
, ' ' ' 
HTi, 5-HT2, and 5-HT3 receptor families) [177]. The 5-HTi family has the highest 
affinity for 5-HT and is coupled to an inhibitory G protein that inhibits adenylyl cyclase. 
The 5-HT2 family displays a relatively low affinity for 5-HT and high affinity for 5-HT 
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antagonists, and is linked to phosphotidylinositol turnover. The 5-HT3 receptor family 
mediates the excitatory effects of 5-HT [ 177]. 
In the kidney, the 5-HTIA and 5-HT18 receptors have been located [163, 178], but 
the antinatriuretic effect of 5-HT is attributed to the 5-HTIA receptor in the rat [163]. 
Histochemical mapping of 5-HT1A receptors is identical in human and rat kidneys, and 
the receptor is found in the thick ascending limb, distal convoluted tubule, connecting 
tubule, and principal cells of the cortical collecting duct [179]. 
2.4.6 Atrial Natriuretic Peptide 
Atrial natriuretic peptide (ANP) is a peptide hormone secreted by the atria of the 
heart in response to increased vascular volume [180, 181]. In the vasculature, ANP 
reduces blood pressure by inhibiting sympathetic output and by ANP-receptor mediated 
relaxation of vascular smooth muscle cells [181]. ANP also inhibits renin and aldosterone 
secretion, and in the kidney ANP stimulates natriuresis and diuresis [182-184]. 
ANP binds to cell surface natriuretic peptide receptors (NPRs). There are three 
NPRs (NPRl, NPR2, and NPR3), each with a single transmembrane region and an 
extracellular binding domain [ 185]. NPRl is expressed in th.e kidney, vasculature, · and 
adrenal glands. NPR2 is found in the brain and pituitary gland and may have a role in 
neuroendocrine regulation. NPR3 is the most widely expressed, being found in most of 
the major endocrine glands, kidney, vasculature, and lungs [185]. 
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In the rat and rabbit IMCD, ANP inhibits sodium reabsorption [186-190] and AVP-
stimulated osmotic water permeability [186, 189]. ANP exerts this action through the 
second messenger cGMP, which inhibits sodium reabsorption by reducing the open 
probability of the ENaC channel [191]. The mechanism by which ANP inhibits water 
permeability has not been determined, but does not appear to involve inhibition of cAMP 
accumulation within the cell [192, 193]. In the CCD, reports of the effects of ANP are 
contradictory. ANP has been reported to inhibit chloride transport in the presence and 
absence of AVP, and to inhibit water absorption by 50% in isolated rabbit tubules [9, 
194]. In contrast, more recent reports in the rat CCD could find no effect of ANP on 
sodium or water permeability [195-197]. 
2.4. 7 Urodilatin 
Urodilatin is a member of the family ofnatriuretic peptides, and is processed to a 23-
amino acid peptide hormone from the same precurser as ANP [198]. It is synthesized in 
renal distal tubule and connecting tubule epithelial cells and interacts with luminal 
receptors to regulate sodium and water reabsorption. Urodilatin binds to the NPRl 
receptor (also called NPR-A receptor) in the same way as ANP, and stimulates formation 
of cGMP [199]. cGMP-dependent protein kinase is then activated which in turn inhibits 
sodium reabsorption via the amiloride-sensitive ENaC channel (discussed in section 2.3.1) 
[200]. Further sodium regulation occurs by inhibition of renin secretion and inhibition of 
the stimulatory effect of angiotensin II on aldosterone release [198]. In addition, 
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relaxation occurs in kidney arterial smooth muscle via a reduction of intracellular calcium 
levels [201]. 
The primary role of urodilatin is natriuretic and diuretic [202, 203]. In humans, 
urodilatin induces strong diuresis and natriuresis under different sodium diets [203]. In 
rats, urodilatin increases urine flow and sodium excretion, and reduces blood pressure 
[183]. Microperfusion studies demonstrate that urodilatin induces sodium and water 
reabsorption in the rat IMCD [190,204]. To date, there is no evidence that urodilatin has 
any effect in the CCD [190, 197]. 
2.4.8 Endothelin 
Endothelins (ETs) are a family of endothelial cell-derived vasoactive substances [205] 
of which here are three members (ET-1, ET-2, and ET-3) [206]. ET-1 is made by 
endothelial cells, airway epithelial cells, macrophages, fibroblasts, cardiomyocytes, and 
some neurons [205]. More recently, IMCD cells have been shown to produce ET-1 
[207]. ET-2 is expressed in intestinal epithelial cells and ET-3 is expressed in intestinal 
and renal tubular epithelial cells and neurons [205, 208]. 
Two ET receptors (ETA and ET B) have been identified in mammals and both contain 
7 transmembrane regions [209]. Each receptor activates an overlapping set of G proteins, 
leading to diverse responses such as activation of phospholipase C and increases in 
intracellular calcium [210]. ETA has higher affinity for ET-1 and ET-2 over ET-3, and 
ETB has equal affinities for all three endothelin peptides [209]. ETA and ETB receptors 
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have been identified in vessel and airway smooth muscle cells, heart, liver, brain, bone, 
kidney, and within the reproductive tract [209]. In the rat kidney, ETA receptor mRNA 
is found only in the glomerulus, arcuate artery, and vasa recta whereas ET 8 receptor 
mRNA is found in those locations as well as the medullary and cortical collecting duct 
[211,212]. 
Endothelin, specifically ET-1, has direct tubular actions that appear to be 
localized mainly to the IMCD where it inhibits A VP-stimulated cAMP accumulation and 
osmotic water permeability [213-215]. The effects ofET-1 on sodium transport has been 
further explored· in rats lacking the ET 8 receptor gene which results in a salt-sensitive 
hypertension [216]. In another study, rats treated with deoxycorticosterone acetate 
(DOCA) exhibited significant hypertention when an ET8 receptor-specific antagonist was 
administered [21 7]. These findings indicate that the effects of ET-1 on sodium transport 
are mediated by the ET 8 receptor in the rat IMCD, which acts by tonically inhibiting 
ENaC activity [215-217]. 
2.5 Membrane Receptors in the CCD 
The CCD is a major site of hormonally regulated sodium and water transport 
and each hormone binds with varied affinity to specific receptors. Section 2.4 reviewed 
some of the major hormones influencing sodium and water permeability in the kidney. 
The present section details vasopressin and adrenergic receptor structure and function, 
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and introduces imidazoline and Y receptors as modulators of A VP-stimulated sodium and 
water permeability. 
2.5.1 Vasopressin Receptors 
A VP acts on at least two types of receptors, V 1 and V 2, classified by their second 
messengers. Both contain seven hydrophobic transmembrane domains characteristic of G 
protein-coupled receptors [218-220]. In addition both are found in the kidney, but with 
distinct mechanisms of action [221-223]. The V 1 receptor is coupled to phospholipase C 
and therefore produces 1,2,4-inositol triphosphate and diacylglycerol. This leads to 
mobilization of intracellular calcium and inhibition of cAMP formation via calcium-
dependent prostaglandin synthesis [223], and influences blood pressure, glycogenolysis, 
and liver regeneration [224, 225]. This V 1 receptor has been further subdivided into V la 
and V lb subtypes. The V la is found in many tissues, including the kidney [222, 226, 227] 
where it appears to be associated with interstitial cells and in vascular elements adjacent 
to collecting ducts [222, 226]. The V1b receptor has been localized to the anterior 
pituitary [228]. 
The V2 receptor is coupled to adenylyl cyclase and has been shown to mediate the 
antidiuretic effects of AVP in the collecting duct [3, 47, 221] (diagram 3, page 9). AVP 
stimulates sodium and water transport from the basolateral, but not the apical, side of 
collecting duct cells indicating that the V 2 receptor is localized to the basolateral 
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membrane [141,143,229]. The specific site of hormone binding is found on the second 
extracellular domain of the receptor [230]. 
2.5.2 Adrenergic Receptors 
Adrenergic receptors, or adrenoceptors, are divided into two families (a and B) and 
can be distinguished pharmacologically based on their responses to epinephrine, 
norepinephrine and isoproterenol [231,232]. The a adrenoceptors are responsive to the 
naturally occurring catecholamines epinephrine and norepinephrine but show only a weak 
response to the synthetic agonist isoproterenol [232]. The B receptors are characterized 
by a strong response to isoproterenol and lower response to the natural catecholamines 
[231]. 
The a receptors are divided into subtypes, a 1 and a 2, based on their affinity for 
agonists and antagonists. The a1 receptor has a higher affinity for phenylephrine than do 
the a 2 receptors, whereas clonidine and yohimbine selectively bind to the a 2 receptors 
with less effect on the a 1 receptors [233, 234]. Binding to a 1 receptors initiates a G 
protein mediated activation of phospholipase C and leads to the release of calcium from 
the endoplasmic reticulum in smooth muscle cells [235]. In contrast, the effect of a2 
receptor binding is an inhibition of adenylyl cyclase and a decrease in intracellular cAMP 
and is mediated by a pertussis-toxin sensitive inhibitory G protein [232]. 
Binding studies have identified at least three subtypes of the a 2 adrenoceptor ( a 2A, 
a2B, and a2c), all of which are activated nonselectively by epinephrine and 
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norepinephrine [233, 236-240]. All of the a 2 subtypes can be blocked by yohimbine and 
rauwolscine, although the affinity varies [241]. The a 2A subtype is widely distributed in 
tissues and has a higher affinity for oxymetazoline over prazosin. The a 2B subtype is 
also widely distributed but has a higher affinity for prazosin than for oxymetazoline 
[237]. The a 2c receptor is expressed in the opossum kidney (OK) cell line [242]. An 
additional subtype, a 20, has been found in bovine pineal gland and may represent a 
species homologue of the a 2A subtype [243]. 
Clonidine has been characterized as the prototypical a 2 agonist which inhibits A VP-
stimulated water and sodium permeability [244]. Y ohimbine is the prototypical a 2 
antagonist and reverses the effects of clonidine [234]. The non-selective endogenous 
adrenergic agonist epinephrine and the arselective agonist dexmedetomidine have also 
been shown to completely inhibit A VP-stimulated transport in the collecting duct [7, 8, 
29], and other agonists and antagonists have been tested with varied degrees of inhibition 
at given concentrations. 
2.5.3 lmidazoline Receptors 
Recently, a new class of receptors called imidazoline (1) receptors have been 
implicated in this A VP-mediated event. Imidazolines are compounds that contain an 
imidazole ring structure (diagram 6) and include some adrenergic agents [21,245,246] (see 
appendices A and B). Clonidine, for example, is an a 2 agonist that is also an imidazoline. 
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The antihypertensive action of clonidine was originally thought to be via a2 
adrenoceptor activation in the central nervous system. [244]. It has since been shown that 
the effect of clonidine is mediated, at least in part, by activation of specific im.idazoline 
receptors [21, 247, 248]. Studies in the rat kidney have shown that activation of I 
receptors increases sodium. and water excretion [15, 16, 249]. 
H 
Diagram 6. Imidazole Ring Structure. The im.idazole ring m.ay be attached to 
NH or to C of the side group. 
Like the adrenergic receptors, I receptors are subdivided into I 1 and h subtypes that 
bind with varied affinity to different agonists and antagonists [250, 251]. The 11 receptor 
displays a high affinity for clonidine by preferentially binding [3H]-pNHrclonidine and 
[3H]-clonidine, and is thought to mediate the· fall in arterial pressure attributed to 
im.idazolines [24, 247, 248, 252, 253]. The pharmacologic profile shows the highest 
affinity for im.idazolidines (im.idazoline ring attached to NH) such as clonidine and 
m.oxonidine, medium. affinity for im.idazolines (im.idazoline ring attached to C) such as 
idazoxan and phentolam.ine, and low affinity for guanidines and guanidides (guanabenz, 
am.iloride) [254]. 
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The 11 receptor site is selectively localized to plasma membranes [254] and has been 
shown to act via a pertussis toxin-sensitive G protein [28]. Activation of the receptor 
leads to production of the second messenger diacylglyceride through direct activation of 
phosphatidylcholine-selective phospholipase C. 11 receptor stimulation in PC12 cells 
(pheochromocytoma cells which lack a2 receptors) also elicits release of arachidonic acid 
and prostaglandins, resulting from the action of diacylglyceride lipase on accumulated 
diacylglyceride [24]. The 11 receptor may be further divided, based on the affinity for 
cimetidine, into subtypes 11A (cimetidine-sensitive) and 128 (cimetidine-insensitive) [255]. 
The 12 receptor preferentially binds [3H]-idazoxan and [3H]-cirazoline and its 
pharmacologic profile shows the highest affinity for imidazolines (idazoxan, cirazoline) 
with a low affinity for clonidine [250, 256]. These receptors are found associated with 
mitochondrial membranes, with the receptor site located mainly on the external membrane 
of the mitochondria. The Ii receptor is associated with the monoamine oxidase (MAO) 
system, with no involvement of G proteins [257, 258]. This mitochondrial specific 
binding site may be associated with the catalytic site of the MAO enzyme, and therefore 
may be a regulatory site [259]. In addition, 12 receptors in different tissues have been 
shown to display high and low affinities for amiloride supporting the existence of Ii 
receptor subtypes, 12A (amiloride-sensitive) and I28 (amiloride-insensitive) [250, 258]. 
The discovery of the· first candidate for an endogenous imidazoline receptor ligand 
actually occurred before the characterization of imidazoline receptors as separate from a2 
. receptors. In 1984, clonidine-displacing substance (CDS) was purified from human brain 
and shown to displace [3H]-clonidine with high affinity, although it was thought at the 
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time to be due to its a2 selectivity [260]. Later, CDS was found to competitively bind 
with high affinity to I receptors [22] but its structure remained unknown. 
In 1994, a CDS called agmatine was isolated from bovine brain. Agmatine, an 
arginine metabolite, binds with high affinity to a2, I 1 and Ii receptors making it the first 
endogenous imidazoline receptor ligand of known structure [261, 262]. Further studies 
have found that agmatine displays preferential affinity for the 11 binding site [263-265]. 
In human platelets the affinity of agmatine for the 11 receptor subtype was 2200-fold 
greater than that of the Ii subtype, 1400-fold greater than that of the a2A adrenoceptors, 
5000-fold greater than the a28 adrenoceptors, and 800-fold over the a 2c adrenoceptors 
[264]. 
Agmatine may be an important neurotransmitter in mammals. It is synthesized in 
the brain and stored in synaptic vesicles in axon terminals [266]. Agmatine is released by 
depolarization in a calcium-dependent manner and is inactivated by reuptake or 
enzymatic degradation [267]. Reuptake into synaptosomes is calcium-dependent and 
inhibited by calcium channel blockers [268]. Enzymatic degradation occurs through the 
action of agmatinase, which hydrolyses agmatine to putrescine and urea [269]. 
The substrate for the production of agmatine is arginine, which enters the cell by 
facilitated transport and is converted via the enzyme arginine decarboxylase (ADC) on 
the mitochondrial membrane [269]. Once synthesized, agmatine can bind to 12 receptors 
on the mitochondrion or to a2 adrenergic, and possibly I 1 receptors on the plasma 
membrane. It may also be released extracellularly since agmatine has been found in 
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plasma. The synthesis of agmatine is thought to be regulated by feedback inhibition of 
ADC within the cell [270](diagram 7). 
Diagram 7. Biosynthesis of Agmatine. Arginine is converted to agmatine by 
arginine decarboxylase located in the mitochondrial membrane. Agmatine may 
bind to imidazoline receptors on the mitochondrial membrane, or leave the cell 
and bind to imidazoline or alpha 2-adrenergic receptors on the plasma 
membrane. Arg, arginine; Agm, agmatine; ADC, arginine decarboxylase; I1R 
and I2R, imidazoline receptors; a2AR, alpha 2-adrenergic receptor. 
Although it was previously known to occur in plants, bacteria, and lower life forms, 
the discovery of ADC in rat brain indicates that the source of agmatine is endogenous 
since ADC is the enzyme involved in the rate-limiting step in agmatine biosynthesis. Of 
additional interest is the localization of ADC to mitochondrial membranes since that is 
also the location ofl2 receptors [261]. Agmatine has been shown to be widely distributed 
in the body with its rank order of concentration being stomach > small intestine >> 
adrenal> heart> brain> plasma [262]. ADC activity has been identified in the kidney 
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cortex and medulla and diamine oxidase, an enzyme shown to metabolize agmatine, has 
been localized to the kidney glomeruli [269]. 
Relatively little is known about the biological actions of agmatine. It is a cation and 
has been shown to open: up some ion channels by activation of nicotinic acetycholine 
receptors [271]. Agmatine may also have a role in insulin-glucose metabolism since it was 
shown to facilitate the release of insulin from pancreatic cells exposed to glucose [272]. 
What is known is that agmatine does not mimic the actions of clonidine completely. 
Agmatine does not contract vascular smooth muscle and is thought to decrease 
sympathetic nerve activity and arterial pressure when injected i.v. by blocking 
sympathetic ganglionic transmission [270]. 
In rats, microperfusion of agmatine into renal interstitium and the urinary space of 
the surface glomeruli produces reversible increases in the single nephron filtration rate 
(SNFR) and absolute proximal reabsorption (APR). Yohimbine (an a.2 antagonist) 
produced the opposite effects and BU-224 (an 12 agonist) duplicated agmatine's effects 
on SNFR but did not effect APR [269]. Thus the effects of agmatine on SNFR and APR 
appear to be dissociable and mediated by different mechanisms and may constitute a 
novel endogenous regulatory mechanism in the kidney. 
· 2.5.4 Y Receptors (Neuropeptide Y and Peptide YY) 
NPY and PYY bind with high affinity to Y receptors, so named because they have 
many tyrosine residues, and have been shown to affect salt and water transport in the 
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kidney. NPY and PYY are both members of the pancreatic polypeptide family that also 
contains pancreatic polypeptide (PP) [273]. 
NPY is a neurotransmitter that is widely distributed in central and peripheral neurons 
and is co-stored and released with norepinephrine (NE) from perivascular nerve fibers 
upon sympathetic stimulation [274]. Coexisting NPY and NE act synergistically to 
regulate renal tubular Na/K-ATPase activity [275-278] and NPY has been shown to 
potentiate the effects of NE by sensitization of arteries. This effect occurs 
postjunctionally [274, 279] and depends on the presence of sodium [275]. In the CCD, 
NPY decreases A VP-stimulated hydraulic conductivity and cAMP was found to play a 
role in this response [26]. 
While NPY is considered a neurotransmitter, the structurally related PYY is a gut 
hormone found in the small intestine and colon. PYY is released from the endocrine cells 
of the lower intestine in response to food and acts on the gastrointestinal system to slow 
intestinal motility and increase intestinal transport of salt and water [280, 281]. In the 
CCD, preliminary studies have indicated that PYY decreases sodium transport [32]. 
NPY and PYY both act on Y receptors which are found in many tissues, including 
the kidney where they have segment-dependent effects in the nephron [13, 32, 282, 283]. 
Binding studies have identified up to five Y receptor subtypes (Y1-Y5) [284]. NPY and 
PYY bind equally well to the Y 1 and Y 2 receptors, both of which have been found in the 
kidney [285]. The Y3 receptor has a higher affinity for NPY over PYY [286] while the Y4 
receptor binds only PP with high affinity [287] and neither has been localized to the 
kidney. The Y5 receptor is localized to the brain [287,288] and binds NPY, PYY and PP 
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where it is involved in the regulation of feeding behavior [289]. The Y5 receptor has also 
been indicated in some of the renal effects ofNPY [32]. 
All of the known Y receptors are coupled to pertussis toxin-sensitive G-proteins 
[34]. The signalling mechanisms for the different receptor subtypes appear to be similar, 
although no distinct signal transduction pathways have been identified. Inhibition of 
adenylyl cyclase is the typical response as with other G/G0 -coupled receptors [290], but 
other responses have been reported. These include inhibition of calcium channels [34, 
278] and stimulation ofNa/K-ATPase activity [277,278]. 
2.6 Signalling Pathways and Second Messengers in the CCD 
A VP action represents the prototypical example of a hormonal effector acting 
through a stimulatory G protein and adenylyl cyclase activation of cAMP-dependent 
signalling in the CCD (see section 2.5.1). Protein kinase A (PKA) is a known second 
messenger in this system, but much of the signal transduction pathway remains unknown. 
This section reviews G proteins and some of the second messengers and pathways that 
are involved in regulation of AVP-stimulated sodium and water transport in the CCD. 
These second messengers and pathways include adenylyl cyclase, PKA, 
phosphotidylinositol hydrolysis, protein kinase C (PKC), prostaglandins, and calcium. 
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2.6.1 G Proteins 
G proteins are a family of proteins involved in a variety of signal transduction 
pathways, including phospholipid metabolism, intracellular vesicle trafficking, and ion 
channel regulation [27, 291]. These proteins are divided into two major classes, 
heterotrimeric G proteins and monomeric G proteins. 
The heterotrimeric G proteins have a high molecular weight and consist of three 
subunits: a (Mr 39,000-52,000), ~ (Mr 35,000-36,000), and "{ (Mr 8,000-10,000). There 
are various heterotrimeric G proteins, characterized by their a subunits because they are 
the most diverse and are thought to be responsible for the specificity of receptor and 
effector interactions [292-294]. The most important ones that act in the kidney are Gs, a 
stimulatory G protein that activates hormone-sensitive adenylyl cyclase [295] and Gi, an 
inhibitory G protein that inhibits adenylyl cyclase. 
The monomeri~ G proteins have a low molecular weight and consist of a single a 
subunit (Mr 19,000-29,000). These proteins have been shown to be important in target 
protein regulation and oncogenesis, and include the Ras and Rab family of proteins [291]. 
Both classes are defined by the ability of the a subunit to bind and hydrolyze guanine 
nucleotides [27]. 
G protein-mediated signals are initiated via binding by G protein-coupled receptors 
(GPCR). The GPCRs all have seven membrane-spanning domains of 20-25 hydrophobic 
residues in the form of a-helices. There is an extracellular amino terminus, three 
extracellular loops, three intracellular loops, and an intracellular carboxyl terminus. 
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Agonists interact with the extracellular and transmembrane domains. The intracellular 
domains interact with G proteins which contain phosphorylation sites and transduce the 
signal to the interior of the cell [296](diagram 8). 
Extracellular Side 
2 3 4 5 6 7 
Cytoplasmic Side 
COOH 
Diagram 8. Topology of the G Protein-Coupled Receptor. The family of G 
protein-coupled receptors all contain 7 transmembrane regions, an amino 
extracellular terminus, a carboxyl intracellular terminus, and 3 intracellular 
loops involved in G protein binding. 
In renal epithelia, G proteins mediate A VP-stimulated sodium and water 
permeability through a basolateral Gs mechanism, and this action can be modulated by 
different receptors through a Gi mechanism [218, 294, 297]. The Gs protein stimulates 
adenylyl cyclase which in turn causes an accumulation of cAMP within the cell. The 
increase in cAMP activates PKA [298, 299] and leads to the insertion of water channels 
and sodium channels into the apical membrane. Activation of a basolateral Gi protein by 
a-adrenergic agents inhibits sodium and water permeability [7, 29, 300] by mechanisms 
not yet fully understood ( diagram 9). 
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Diagram 9. Alpha-2 Receptor in the Principal Cell. Alpha-2 (a2) agonists 
bind to the aradrenergic receptor and inhibit AVP-stimulated water and 
sodium permeability. 
The signalling pathways for A VP-stimulated sodium and water transport in the CCD 
and inhibition of this transport are not completely known, but it has been shown that 
second messengers in addition to cAMP are involved [29, 30, 301]. These second 
messengers may include calcium [302], PKC [44, 298, 303, 304], and prostaglandin E2 
[305-308]. 
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2.6.2 Adenylyl Cyclase and cAMP 
Adenylyl cyclase (AC) integrates the positive and negative signals that act through G 
protein-coupled receptors to regulate intracellular levels of cAMP [27]. The structure of 
AC consists of two subunits (Ml and M2) with six transmembrane domains each [309]. 
There is a large cytoplasmic loop between the two subunits (Cl) and a large extracellular 
loop between transmembrane regions 9 and 10 that is the site for glycosylation [310]. 
There are at least 9 isoforms of mammalian AC identified so far [311-315]. All of the 
isoforms have been found in the brain and all are stimulated by the Gs a subunit of the G 
protein, and this requires both the Cl domain as well as the carboxyl terminus [316]. The 
inhibitory Gia subunit inhibits only AC types 1, 5, and 6, and occurs in the Cl regions 
of AC types 1 and 5 [317]. In the principal cell of the rat collecting duct, the type 6 AC 
isoform has been localized where it elicits a calcium-dependent inhibition of cAMP [318]. 
The ~y subunit of the G protein inhibits type 1 and stimulates types 2 and 4 [310, 319] 
and occurs in the Cl region of the AC type 1 isoform [317]. 
2.6.3 Protein Kinase A 
Binding of the a subunit of the G protein to adenylyl cyclase activates the enzyme 
which in turn catalyzes the conversion of ATP to cAMP [319]. cAMP is bound to PKA 
enzymes, which are composed of two regulatory and two catalytic subunits [320]. The 
PKA catalytic subunits, which are the main effectors of cAMP, dissociate from cAMP-
saturated regulatory subunits and phosphorylate numerous downstream targets. 
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Diversification of the pathway occurs at the PKA level because various PKA anchoring 
proteins (AKAPs) can sequester PKA molecules until the arrival of cAMP [321, 322]. 
The AKAPs represent a family of functionally related molecules characterized by their 
interaction with the type I or type II regulatory subunits of PKA. In addition, AKAPs 
contain unique targeting sequences that direct the PKA-AKAP complex to specific 
intracellular locations [321]. .One of these targets is the aquaporin 2 water channel (AQP-
2), which is translocated to the apical membrane upon phosphorylation [323]. 
2.6.4 Phosphotidylinositol Breakdown 
One of the ways that vasopressin increases levels of calcium within the cell is by 
initiating calcium release from intracellular stores, which is dependent on inositol-1,4,5-
trisphosphate (IP3) generation [302]. Phospholipase C (PLC) hydrolyzes phosphotidyl-
inositol bisphosphate (PIP2) into two breakdown products, diacylglycerol (DAG) and 
IP3• IP3 initiates the mobilization of calcium [324, 325] and DAG in the presence of 
calcium directly binds to and activates PKC. The increase in calcium may also lead to 
activation of other calcium-dependent kinases [302]. 
2.6.5 Protein Kinase C 
The ultimate consequence of DAG formation is the activation of PKC. PKC 
represents a family of enzymes that phosphorylate serine or theonine residues on various 
intracellular proteins and are responsible for a wide range of cellular functions. There are 
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12 isozymes identified so far and they are classified into three subfamilies [326]. The 
classical PKC ( cPKC) includes the a, ~I, ~II, and y isozymes and is dependent on 
activation through cofactors like DAG and calcium. The second group includes the novel 
PKC (nPKC) including 8, E, 0, Tl, and µ, and are also activated by DAG but are calcium 
independent. The third group, or atypical PKC ( aPKC), includes ~' t, and "A, and require 
only phosphotidylserine for activation [324, 326]. Of all the PKC isoforms, only PKCa 
has been localized to the CCD [326]. As with PKA, anchoring proteins play an integral 
part of PKC activity. These anchoring proteins for PKC are called RACKs (receptors for 
activated C-kinase) [327, 328] and have been proposed to impart isozyme selectivity 
within the cell [328]. 
2.6.6 Prostaglandins 
Prostaglandins (PGs) are a family of diverse autocoids derived from the 
cyclooxygenase-mediated metabolism of arachadonic acid. Five primary prostanoids are 
produced and each one· interacts with a different G protein-coupled receptor [329]. 
PGE2 is produced in the kidney and the highest rate of synthesis occurs in the collecting 
duct where it plays a role in salt and water transport [329]. Studies investigating the 
effects of exogenous PGE2 administration demonstrate varied results depending on the PG 
receptor involved as well as major species differences [6, 10, 330]. In the rat CCD, 
exogenous PG has little effect on AVP-stimulated salt or water transport [6, 330, 331]. 
Endogenous PG production however, has been shown have an antinatriuretic and 
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antidiuretic effect by reversing alpha-2 adrenoceptor effects [332]. This occurs by a 
direct stimulation of PG synthesis by vasopressin [329, 333]. The mechanism of action 
of PGE2 may involve release of calcium from intracellular stores and subsequent 
activation of PKC [10,306]. 
2.6.1 Calcium 
In the mammalian collecting duct, A VP increases intracellular free calcium 
concentrations [334-336]. AVP binds to two receptors: V1 receptors which activate 
phospholipase C and release intracellular calcium through phosphotidylinositol 
hydrolysis [302]; and V2 receptors which are coupled to adenylyl cyclase and cAMP 
generation ( discussed in section 2.1.5). Radioligand binding studies have shown that the 
V 2 receptor is more abundant in the collecting duct, and that the V 1 receptor is localized in 
vascular and interstitial cells rather than in tubules themselves [221]. In addition, AVP 
was shown to increase intracellular calcium levels in mouse collecting duct cells and 
isolated rat IMCDs independent of adenylyl cyclase activation [336-338]. 
Two phases of cellular free calcium mobilization are evident after the addition of 
A VP. There is an early phase derived from the intracellular calcium· pool and a sustained 
phase that depends on extracellular calcium [325, 335]. In rabbit CCDs, reduced 
extracellular calcium causes a reduction in the hydrosmotic effect of AVP [339-341]. 
Evidence suggests that calcium inhibits A VP action by stimulation of PLC and the 
subsequent activation of PKC inhibits cAMP formation [341]. 
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In summary, the mammalian nephron regulates blood pressure and plasma 
osmolarity, and reabsorption of sodium and water in the collecting duct is the final step of 
this regulation. The cortical segment of the renal tubule contains principal cells that 
possess water channels, ion channels and ion transporters. The tubular reabsorption of 
sodium and water is under hormonal stimulation and the influence of some of the major 
players is shown in table I. In addition, multiple second messengers and signalling 
pathways are implicated in these responses, including G proteins, adenylyl cyclase, 
' 
PK.A, PKC, prostaglandins, and calcium. 
Hormone Sodium reabsorption Water reabsorption 
Aldosterone stimulates stimulates 
V asopressin stimulates stimulates 
Epinephrine inhibits inhibits 
Dopamine inhibits inhibits 
Serotonin stimulates stimulates 
Atrial Natriuretic Peptide inhibits inhibits 
Urodilatin inhibits inhibits 
Endothelin inhibits inhibits 
Table I. Hormonal Effects on Sodium and Water Reabsorption in the CCD. 
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Chapter Ill 
RESEARCH DESIGN AND METHODS 
3.1 Animals 
Young, pathogen-free Sprague-Dawley rats (50-100 g body weight) were obtained 
from the Oklahoma State University College of Osteopathic Medicine animal facility or 
purchased from Harlan Sprague-Dawley Inc. (Indianapolis, IN). Animals were housed in 
a separate room in the animal facility in plastic bins with adequate bedding, and 
maintained on standard rat chow and tap water ad libitum. Rats were kept on a 12 hour 
light and 12 hour dark cycle. Some of the rats were given a low sodium diet to allow for 
more pronounced electrophysiological responses due to increased levels of endogenous 
mineralocorticoids which increase sodium transport. Animal facilities were under the 
direction of full-time animal caretakers, and this project was approved by the Oklahoma 
State University College of Osteopathic Medicine Animal Use Committee. The College 
of Osteopathic Medicine complies with the NIH policy of animal welfare of the Animal 
Welfare Act and all other applicable laws. 
All animals were kiUed by decapitation. Although the Panel on Euthanasia of the 
American Veterinary Medical Association recommends anesthesia before decapitation, it 
has been found that decapitation can be accomplished rapidly in these small rats with a 
minimum of excitement in comparison to the restraint and injection of anesthetics. In 
addition, many circulating hormones affect the transport characteristics of the collecting 
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duct, so excessive handling of the animals may alter plasma levels of adrenal corticoids, 
catecholamines, and vasopressin. 
3.2 Isolation and Perfusion of Renal Tubules 
After decapitation, both kidneys were removed and placed in cold dissecting solution 
containing 6% bovine albumin. The kidney capsules were removed and 4 or 5 cross-
sectional slices were cut from each kidney and placed in a chilled (-1 7°C) dissection 
solution in order to slow metabolic processes temporarily. A section of the cortical 
collecting duct (CCD) was then dissected from the renal slices and was identified by the 
presence of specific morphological and structural features [36, 342]. 
The isolated CCD was transferred to room-temperature bathing solution in a Lucite 
perfusion chamber on the stage of an inverted microscope. The tubule was mounted 
between concentric pipettes and suspended in the bathing solution ( diagram 10). 
Sample$ drawn into 
collection pipette ~ 
Isolated kidney tubule 
Perfusion 
fluid 
Diagram 10. Isolated Perfused Tubule Technique. A single cortical 
collecting duct is suspended from concentric pipettes in a bathing solution on 
an inverted microscope. A perfusion solution is moved through the tubule 
using air pressure. All solutions were maintained at 3 7° C. 
On the perfusion side of the suspended tubule, an inner pipette was inserted into the 
tubular lumen and perfusion was initiated using air pressure. The other end of the tubule 
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was held in place by the tip of the collection pipette, which had been dipped in Sylgard 
(Dow-Coming, Midland, MI) to provide a seal so that the luminal perfusate was 
completely isolated from the bathing solution. The bathing solution flowed constantly 
from a temperature regulated reservoir so changes in the bathing solution could occur 
without a change in temperature. 
3.3 Solutions 
The compositions of the bath, perfusion, and dissecting solutions are shown in table 
II. Perfusion and bath solutions were bubbled with a 95% 0 2/5% CO2 gas mixture for 30 
minutes prior to use. All concentrations are in mM and the dissecting solution contained 
6% bovine albumin to keep the tubule from sticking to the glass dissecting chamber and 
transfer pipette. 
BATH PERFUSION DISSECTING 
NaCl 130 88 106 
NaHC03 25 25 
KCl 5 5 5 
Glucose 5 0.5 8.3 
MgC}i 1 0.5 0.5 
CaC12 1.5 1.5 1.5 
Phosphate Buffer 2 2.5 2 
Na Acetate 5 5 5 
Urea 1 
pH 7.4 6.6 7.4 
Osmolality (mOsm) 295 184 296 
Table II. Composition of Solutions. 
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3.4 Osmotic Water Permeability (Flux) Experiments 
3.4.1 Determination of P1 
As noted above, the perfusate was made hypotonic to the bathing solution (184 vs 
310 mOsm/Kg H20) in the flux experiments in order to create an osmotic gradient across 
the epithelium. Dialized 3H-methoxy inulin or 14C-carboxyl inulin was added to the 
perfusate as a volume marker. Samples of perfusate were collected in a calibrated 
volumetric pipette and counted in a scintillation counter. 
Perfusion rate (Vi) was determined as 
Vi= (V0 ) 3H0/3Hi 
where 3H0 is the inulin concentration in the collection pipette and 3Hi is the inulin 
concentration in the perfusate. VO is the rate of collection and was measured directly as 
the time to fill a calibrated constant volume pipette. 
Hydraulic conductivity (Lp) was determined as 
Lp = ViC/RTA[(Ci-Co)/(CiCoCb) + (l/Cb)2 ln ((Co-Cb)Ci)/((Ci-Cb)Co)] 
where Ci, C0 , and Cb is the osmolality in mOsm/kg H20 for perfusate, collected fluid, and 
bath, respectively. R is the gas constant, Tis the temperature in °K, and A is the tubular 
area in cm2 calculated from the measured tubule length and internal diameter [343]. 
Osmotic water permeability (Pf) was determined as 
Pf= (Lp) RT N w where V w is the molar volume of water. 
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In the CCD, the Pr in the absence of AVP is near zero as apical water channels are 
confined to intracellular vesicles [4, 8, 154]. Reif et al [142] report basal Pr values in the 
rat CCD in the absence of AVP to range from 20-30 µm/sec and to increase to over 400 
µm/sec with AVP stimulation. Chen et al [144] report that 220 pM AVP increases Pr 
from Oto 981±120 µm/sec in isolated rat CCDs. Studies by Hawk et al [344] and Rouch 
et al [7, 8] found basal Prto range from Oto 35 µm/sec, and to be increased with 220 p M 
A VP to a range of 602-835 µm/sec. 
3.4.2 Study Design for Flux Experiments 
Once a collecting duct was mounted and perfusion was initiated, the bathing solution 
was slowly warmed to 37°C and equilibrated for 20 minutes. The experiments consisted 
of this initial control period and two to four experimental periods. In each period, three 
individual samples were taken from the collection pipette after a 15-20 minute 
equilibration time and averaged for a single Pr value. Subsequent periods began with the 
addition or removal of an experimental agent to the bathing solution. Dexmedetomidine, 
an a2 agonist that has been shown to inhibit A VP-stimulated permeability by more than 
95%, and atipamezole, an a2 antagonist that has been shown to reverse this inhibition 
were both used at 1 µM [8]. The cAMP non-hydrolyzable analog 8-CPT-cAMP was 
used at 100 µM. Oxymetazoline, WB4101, ARC239, agmatine, idazoxan, and rilmenidine 
were used in 1 µM concentrations. Staurosporine, a PKC inhibitor, was used at 10 nM 
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and 100 nM and indomethacin, a prostaglandin synthesis inhibitor, was used at 5 µM [8]. 
A VP was used at 220 pM [8] and PYY at 10 nM and 100 nM concentrations [345]. 
3.5 Electrophysiology Experiments 
3.5.1 Determination of Ve, Re, Vbl' and fR.a, 
The isolated perfused tubule techneque can also be used to measure the 
electrophysiological parameters across an epithelial layer as depicted in diagram 11. 





Diagram 11. Electrophysiological Measurements in the Principal Cell. V1 is 
the transepithelial voltage and is lumen negative, R1 is the transepithelial 
resistance, V bl is the voltage across the basolateral membrane, and fR.ap is the 
fractional resistance of the apical membrane. 
A Luigs-Neuman (Rattingen, FRG) in vitro perfusion system was used to provide 
electrical sealing on both sides of the suspended tubule (diagram 12). The perfusion 
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pipette was made from double-barrelled theta glass. Electric current from a stimulator 
(Grass S88) was sent through a silver wire inserted into one side of the pipette while the 
other side was used to measure transepithelial voltage (Vt), The double barrel pipette also 
allowed for rapid changes in the luminal perfusate by changing pressure from one side to 
the other via a valve system. 
Electrophysiology in Kidney Tubule 
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Diagram 12. Electrophysiology Experimental Setup. 
explanation. 
See text for 
Vt (m V) was continuously measured through the perfusion pipette which was 
connected to a high impedence electrometer (Keithley 614) by an agar bridge. Another 
agar bridge was inserted into the collection pipette to measure voltage at the other end of 
the tubule. Current pulses of 40-80 nA at 80 msec duration and a rate of 8 pulses/minute 
were injected, and voltage deflections at both ends of the tubule are measured. Rt was 
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calculated according to cable analysis for a terminated cable of length L [346]. The. 
transepithelial length constant of the tubule, At, is determined from the voltage deflections 
at the perfusion end (~V0) and collection end (~VL) of the tubule and is given by the 
following equation 
Transepithelial resistance (in Q-cm2) was determined by the equation 
where Rin is the input resistance measured in ohms (Q) and Ri is the resistance of the 
perfusion solution (in Q-cm) measured using conductance meter (YSI). 
Basolateral membrane voltage (V bI) (in m V) was measured by cell impalement. Single 
barrel microelectrodes made with a vertical pipette puller (Sutter P-30) were filled with 
IM KCl, yielding resistances of 80-200 MQ. The microelectrode was mounted on a 
motorized micromanipulator (Adams and List) and the basolateral membrane impaled 
using a piezoelectric driver (Fine Science Tools PM-10). The microelectrode was 
connected to one channel of the electrometer for intracellular voltage measurements. 
The fractional resistance of the apical membrane (/Rap) was determined from the ratio 
of the voltage deflections across the apical membrane to that of the epithelia at the point 
of impalement and was calculated by the equation 
where Ra and Rb are the apical and basolateral cell membrane resistances, respectively, of 
the impaled cell. 
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Basal sodium transport in the rat CCD in the absence of A VP is very low [2, 8, 11, 
39, 347]. Schafer et al [172] found the basal value of Vt was -2.5±.03 mV and AVP 
hyperpolarized Vt to -19.3±3.2 mV in isolated rat CCDs. Schlatter and Schafer [39] 
report the basal Vt to be -5.1±0.7 mV and Rt to be 51±4 Q-cm2 in the rat CCD. In that 
· study, 220 pM AVP hyperpolarized Vt to -16.1±1.4 mV and decreased Rt to 39±2 
Q-cm2. In addition, data obtained from impaled principal cells show that AVP 
depolarizes the apical membrane from 79±1 to 66±2 mV and decreases .fR.ap from 
0.76±0.04 to 0.70±0.04. Rouch et al [8] report control Vt to be 0±0.03 mV with AVP 
hyperpolarization bringing it down to -2.6±0.2 mV, and control Rt values to be 30±4 
Q-cm2 with A VP decreasing it to 24±5 Q-cm2• 
3.5.2 Study Design for Electrophysiology Experiments 
Once a tubule was mounted on the concentric pipettes, the bathing solution was 
warmed to 3 7°C and equilibrated for 5 -10 minutes. After the control period, A VP was 
added to the bath to stimulate sodium transport. This hyperpolarized Vt and reduced Rt. 
Experimental periods began with the addition or removal of an agent to the bathing 
solution and a minimum of 5 minutes was allowed before proceeding to the next period. 
A cellular impalement may have been obtained once Vt stabilized. A perfusion 
solution containing 10 µM amiloride, a sodium channel blocker, was used to determine if 
the impaled cell was a principal cell. Amiloride completely hyperpolarizes the apical and 
basolateral membranes even in the presence of AVP, indicating that the only route of 
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sodium entry into the principal cells occurs via amiloride sensitive sodium conductance 
[39], and amiloride alters Vb1 in principal cells. Intercalated cells do not contain sodium 
channels and therefore do not show this response. Impalements were considered 
successful if the following criteria were met: I) voltage was reached rapidly upon 
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impalement; 2) voltage remained stable for at least 5 minutes; 3) voltage returned to 
baseline when the electrode was removed from cell; 4) pipette tip resistance did not 
change over the course of the experiment. 
3.6 Statistical Analysis 
The experimental design of these studies allow for each renal tubule to serve as its 
own control with three or four subsequent treatment groups. These types of experiments 
are called repeated-measures designs. The total variability of this design can be broken 
down into three componants: variability between subjects, variability between subject's 
responses, and variability due to the treatments. Repeated-measure designs are more 
powerful than ordinary designs because the variability between subjects can be isolated so 
the analysis can focus more precisely on the treatment effects. The recommended 
approach for analyzing this type of data is called the analysis of variance (ANOVA) 
[348-350]. 
The ANOVA is the multigroup generalization of the t test. Like the t test, ANOVA 
complies with the assumptions that the samples are randomly distributed with the same 
standard deviations. Unlike the t test, the ANOV A compares more than two groups and 
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answers the question of whether or not differences are due to random sampling variation. 
It also protects the researcher by first asking if there are any differences at all among the 
groups. If the ANOV A test is significant then the answer is yes, and the investigator can 
then make comparisons between groups or combinations of groups [349]. 
The F statistic is used to conduct an AN OVA, and is the ratio of population variance 
of means from different treatment groups to an estimate of population variance computed 
from the variance within each treatment group. Therefore, when F is a large number the 
conclusion is that at least one of the treatments had an effect. To answer further 
questions about which treatments had effects, multiple contrasts and comparisons can be 
made. In testing a contrast, the differences of interest are concentrated into a single degree 
of freedom producing a more powerful test. This allows a very specific hypothesis to be 
tested, such as "AVP will increase water reabsorption", after the ANOVA has determined 
that a difference exists [348, 349]. 
Because the design of these experiments allow each individual collecting duct to act as 
its own control and also allows for influences of one expeimental period upon another, the 
one-way ANOV A statistical test is appropriate [348] (Payton, M.E., personal 
communication). A minimum of four and a maximum of eight experiments were 
conducted in each protocol. Results obtained from the experimental periods were 
examined using ANOVAwith repeated measures and significance was determined using 
contrasts between selected periods with the SuperANOV ATM (Abacus Concepts, 
Berkeley, CA) computer program with a level of significance set at P < 0.05. The type 
III sums of squares is designed to remove all the other effects in the model before testing 
60 
the effect in question. This is appropriate when the investigator wants to assess the 
effect of terms in the model when it is felt that each level of the factors in the experiment 
should have equal weight. 
Results from all experiments are shown in graph form and reported as mean ± SE 
(standard error of the mean). This technique of reporting SE is informative but 
misleading. When treatment effects are small and group variability is high, SE bars may 
overlap, leading to the impression that no significant difference exists. This is not 
necessarily true, however, and subsequent conclusions will often be faulty. This method 
does well in representing the relative variability of the data, but researchers should not try 
to draw inference to the equality of the means based on the SE bars, [351]. Raw data and 
statistical values are found in appendix D. 
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Chapter IV 
'SECOND MESSENGERS IN THE ALPHA 2-MEDIATED INHIBITION OF AVP-
STIMULATED TRANSPORT IN THE CCD 
4.1 Introduction 
One of the major stimulators of sodium and water reabsorption in the CCD is 
arginine vasopressin (A VP), and this response is inhibited by alpha-2 (a2) agonists. The 
mechanism of Ui-mediated inhibition occurs through an inhibitory G protein (GJ coupled 
to adenylyl cyclase that blocks the formation of intracellular cAMP from ATP. Recent 
evidence has shown that a 2 agonists are capable of inhibiting A VP-stimulated sodium and 
water transport in the CCD in the presence of non-hydrolyzable cAMP analogs, suggesting 
an alternate signalling pathway [29]. Some of the main intracellular second messengers that 
have been indicated in the mechanism of armediated inhibition of A VP-stimulated 
sodium and water transport include prostaglandins, PKC, and calcium. In the rabbit 
CCD, staurosporine inhibits the prostaglandin Ei (PGE2)-induced reduction in Pr [306] 
and inhibits sodium transport via an increase in intracellular calcium concentrations [352]. 
In mouse distal tubule cells, a2 receptors activate phospholipase C and increase PKC 
activity [353]. In the rat inner medullary collecting duct (IMCD), PGE2 inhibits Pr at a 
post-cAMP site linked to PKC activation [307]. Also in the rat IMCD, indomethacin, a 
known prostaglandin inhibitor, and staurosporine both reverse a2-mediated inhibition of 
AVP- and cAMP-stimulated Pr [30], but such studies have not yet been done in the rat 
J 
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CCD. The purpose of the present study is to determine the effects of decreased 
extracellular calcium levels, decreased intracellular PKC levels, and decreased endogenous 
prostaglandin synthesis on the cx.rmediated inhibiton of A VP-stimulated Pr, V1, and Rt in 
the rat CCD. The hypothesis is that all three second messengers play a role in the CX.r 
mediated mechanism. 
4.2 Methods 
After dissection, CCDs were mounted on concentric pipettes and a control period 
was initiated as described in section 3.2. Nine flux protocols were used, all having an 
initial control period and a second period where 220 pM A VP was added to the bath. 
Protocols are listed in table III. 
Period 










Control AVP AVP AVP 
Control AVP LCAVP AVP Control 
Control AVP AVP+D AVP+D+A 
Control AVP LCAVP+D AVP 
Control AVP LCAVP+D+Q AVP 
Control AVP AVP+D AVP+D+I+S AVP+D 
Control AVP AVP+D AVP+D+I AVP+D 
Control AVP AVP+D A VP+D+S (1 OnM) 
Control AVP AVP+D A VP+D+S (1 OOnM) 
Table III. Protocols to Investigate Second Messengers. 
A VP, arginine vasopressin; LC, 0 .1 µM calcium bath; D, dexmedetomidine; 
A, atipamezole; Q, quin-2AM; I, indomethacin; S, staurosporine. 
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Protocol 1 served as an A VP control experiment to determine the stability of the 
A VP response over three experimental periods. Protocol 2 was to determine if 
extracellular calcium is required for the AVP response, so a low calcium bath (0.1 mM 
Ca21 was substituted for normal bath (1.5 mM Ca21 in one period. This also allowed 
for comparisons between the control experiment and low calcium experiment. Protocol 3 
was done to determine the effect of the a2 agonist dexmedetomidine (1 µM) and a 2 
antagonist atipamezole (1 µM) on A VP-stimulated water transport and served as an a2 
control experiment. Protocol 4 was to determine if extracellular calcium is necessary for 
the a2 effect by investigating the effect of dexmedetomidine in a low calcium bath. This 
allowed for the comparison of protocols 3 and 4. Protocol 5 was done to determine if 
intracellular calcium is required for the a2 effect by investigating the effect of 
dexmedetomidine in a low calcium bath in the presence of an intracellular calcium chelator 
(60 µM Quin-2 AM). 
Protocol 6 was undertaken to determine the combined effect of prostaglandin and 
PKC inhibition on the a2 effect using the prostaglandin synthesis inhibitor indomethacin 
and the PKC inhibitor staurosporine. lndomethacin was used at 5 µM because previous 
studies have shown this concentration to effective in inhibiting prostaglandin effects in 
the rat IMCD [307, 354]. Staurosporine was used initially at 10 nM based on results 
from previous studies in the rat IMCD [307] and rat CCD [8]. Protocol 7 was done to 
determine if indomethacin has an effect by itself. Protocol 8 was undertaken to determine 
if staurosporine has an effect by itself and protocol 9 was done to determine if increasing 
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staurosporine concentration from 10 nM to 100 nM would cause an effect when low dose 
PKC inhibition did not. 
Two additional sets of experiments were conducted usmg electrophysiology 
techniques described in section 3.5 as an indicator of epithelial sodium channel activity. 
These studies mimmicked protocol 2 using a low calcium bath, and protocol 6 using the 
PKC and prostaglandin inhibitors as shown in Table III. 
4.3 Source of Biochemicals 
AVP, quin-2AM, 8CPTcAMP, indomethacin and staurosporine were purchased from 
Sigma Chemical Co. (St. Louis, MO). Dexmedetomidine and atipamezole were obtained 
from Orion Pharma (Turku, Finland) and 3H-inulin was purchased from New England 
Nuclear (Boston, MA). 
4.4 Results 
In protocol 1, A VP significantly increased Pr and maintained it for three consecutive 
periods (figure IA). In protocol 2, this A VP effect was not diminished by substituting 
the normal bath calcium concentration of 1.5 µM with a bath containing only 0.1 µM 
calcium (figure lB). Figure 1 C shows there is no difference in A VP response between 
groups in the . normal bath and. low calcium bath conditions. In protocol 3, 
dexmedetomidine inhibited AVP-stimulated Pr (p<.01) and atipamezole reversed the 
inhibition (p<.05) (figure 2A). In protocol 4, the low calcium bath (LC) did not impair 
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the ability of dexmedetomidine to inhibit A VP-stimulated Pr (p<.05) (figure 2B). Figure 
2C shows there is no significant difference in the effects of dexmedetomidine between 
normal and LC conditions. Of additional interest is the observation that there was no 
significant difference between the final periods which contained A VP, dexmedetomidine, 
and atipamezole in protocol 3 whereas protocol 4 contained only AVP (figure 2C). In the 
fifth protocol, the intracellular calcium chelator quin-2AM was used in conjunction with a 
LC bath, AVP, and dexmedetomidine. In this study, the CCD was in the presence of the 
chelator for 30 minutes. Results indicate that tubule damage occured allowing water to 
leak into the tubule resulting in a negative Pr in the last two experimental periods (figure 
2D). 
In protocol 6, indomethacin and staurosporine were both present in the bathing 
solution. Dexmedetomidine inhibited A VP-stimulated Pr (p<.001) and the addition of 5 
µM indomethacin and 1 µM staurosporine resulted in a 53% reversal (p<.05) (figure 3A). 
All experimental periods are different from the control period (p<.05). The first and 
second A VP+Dex periods were not different from each other and the A VP period is not 
different from the fourth period in which both agents were in the bath. In protocol 7, the 
indomethacin alone study, dexmedetomidine inhibited AVP-stimulated Pr (p<.001) with 
no reversal upon addition of indomethacin to the bath. There was a difference between 
the control period and the first AVP+Dex period (p<.05), but no difference in the fourth 
period in which indomethacin was present or the final A VP+Dex period versus control 
(figure 3B). In protocol 8, with staurosporine at 10 nM, dexmedetomidine inhibited 
AVP-stimulated Pr (p<.001) with no reversal upon addition of 10 nM staurosporine to 
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the bath (figure 3C). Finally, in protocol 9, staurosporine was used at 100 nM and 
reversed dexmedetomide-induced inhibition (p<.05) (figure 3D). 
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(C) 
Figure 1. A VP-stimulated Pr under standard and low calcium conditions. (A) 
A VP time-control study. The sequence of experimental periods is shown on 
the horizontal axis. After the control period, 220 pM A VP was added to the 
bath and Pr increased significantly (p<.001). There was an insignificant 
decrease in Pf in the second and third A VP periods. n=4. (B) Low calcium 
bath does not affect A VP-stimulated Pr- Switching from 1.5 mM 
concentration of calcium to 0.1 mM calcium had no effect on Pr. n=4. (C) 
Standard bath vs low calcium bath. Comparison between normal calcium (1.5 
mM) and low calcium bath experiments shows no difference between groups 
in any period. Solid bars represent protocol 1 and hatched bars represent 
protocol 2. 
AVP, arginine vasopressin; LC, 0.1 µM calcium bath. 
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Control AVP A VP+D A VP+D+A Control AVP LC AVP+D+Q AVP 
(D) 
Figure 2. Dexmedetomidine-induced inhibition of Pr under standard and low 
calcium conditions. (A) Dexmedetomidine inhibits A VP-stimulated Pr- A VP-
stimulated Pr is inhibited with dexmedetomidine (p<.01) and this effect is 
reversed with atipamezole (p<.05). n=4. (B) Low calcium bath does not 
affect dexmedetomidine-induced inhibition of A VP-stimulated Pr· A VP 
stimulates Pr (p<.05) and dexmedetomidine inhibits Pr (p<.01). n=5. (C) 
Standard bath vs low calcium bath. Comparison of two studies shows· no 
difference between normal calcium (1.5 mM) and low calcium conditions in 
any period. Solid bars represent protocol 3 and hatched bars represent 
protocol 4. (D) Low calcium bath with Quin-2 AM. The combination of low 
calcium bath, calcium chelator, AVP, and dexmedetomidine resulted in a Pr 
less than control. Pr continued to decline after removal of chelator and 
dexmedetomidine and return to normal 1.5 µM calcium bath indicating 
irreversible tissue damage. n=3. 
D, 1 µM dexmedetomidine; A, 1 µM atipamezole; Q= 65 µM. 
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Control AVP AVP+D AVP+D+S Control AVP AVP+D AVP+D+S 
(D) 
Figure 3. Effects of staurosporine and indomethacin. (A) Staurosporine and 
indomethacin reverse dexmedetomidine-induced inhibition of A VP-stimulated 
Pr. AVP increased Pr (p<.001) and dexmedetomidine inhibited Pr (p<.05). 
Addition of 5 µM indomethacin and 10 nM staurosporine reversed the 
inhibition (p<.05), and removal of these agents restored the inhibition 
(p<.05). n=4. (B) Indomethacin does not affect Pr. Indomethacin at 5 µM 
does not reverse dexmedetomidine-induced inhibition of A VP-stimulated Pr-
n=4. (C) Low dose staurosporine does not affect Pr. Staurosporine at 10 nM 
does not reverse dexmedetomidine-induced inhibition of A VP-stimulated Pr-
n=4. (D) High dose staurosporine reverses dexmedetomidine-induced 
inhibition of A VP-stimulated Pr- Dexmedetomidine inhibits A VP-stimulated 
Pr and this effect is reversed with 100 nM staurosporine (p<.05). n=5. 
D, Dexmedetomidine; S, Staurosporine; I, Indomethacin. 
t = different from control period. * = different from previous period. 
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In the first electrophysiology experiment, A VP hyperpolarized transepithelial 
voltage CVt) and decreased transepithelial resistance (Rt) indicating an increase in sodium 
reabsorption. The exchange of the 1.5 mM calcium-containing bath for the low calcium 
condition of 0.1 mM calcium did not significantly effect Vt or Rt (figures 4A and 4B). In 
the second electrophysiology study, AVP once again hyperpolarized Vt and decreased Rt, 
The addition of the dexmedetomidine depolarized Vt and increased Rt via its inhibitory 
action on AVP-stimulated transport. The addition of the PKC synthesis inhibitor 
indomethacin and the PG synthesis inhibitor staurosporine caused a slight reversal of 



















Control AVP .LC AVP AVP Control AVP LC AVP AVP 
(B) 
Figure 4. Electrophysiological effects oflow calcium bath. (A) Low calcium 
bath does not affect Vt, AVP (220 pM) hyperpolarized Vt and switching to a 
low calcium bath had no significant effect. (B) Low calcium bath does not 
affect Rt, AVP decreased Rt (p<.05) and the low calcium bath had no effect. 
n=5. 
LC, 0.1 µM calcium bath. 
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Control AVP AVP+D AVP+D+l+S AVP+D Control AVP AVP+D AVP+D+l+S AVP+D 
(B) 
Figure 5. Electrophysiological effects of staurosporine and indomethacin. 
(A) AVP (220 pM) hyperpolarized Vt (p<.001) and dexmedetomidine (1 
µM) depolarized Vt (p<.05). There was no significant reversal of the 
dexmedetomidine effects seen with the addition of 5 µM indomethacin and 10 
nM staurosporine. (B) Staurosporine and indomethacin do not affect Rt, 
AVP decreased Rt (p<.05) and dexmedetomidine increased Rt (p<.05). There 
was no significant reversal of the dexmedetomidine effects seen with the 
addition of indomethacin and staurosporine, however there was a difference 
seen with the removal of the experimental agents (p<.05). n=S. 
D, Dexmedetomidine; S, Staurosporine; I, lndomethacin. 
t = different from control period. * = different from previous period. 
A final flux protocol was added to the study in which indomethacin was added to the 
bath before staurosporine to determine if there is an order effect of these inhibitors. 
Results are shown in figure 6. Indomethacin alone had no effect on dexmedetomidine-
induced inhibition of A VP-stimulated Pf, but the subsequent addition of staurosporine 














AVP+D AVP+D+I AVP+D+l+S AVP+D+I 
Figure 6. Effect of administration order of PG and PKC inhibitors on 
dexmedetomidine-induced inhibition of Pr. lndomethacin (5 µM) had no 
significant effect on dexmedetomidine-induced inhibition, but addition of 
staurosporine decreased Pr (p<.05). Removal of staurosporine from the bath 
had no effect. n=8. 
D, Dexmedetomidine; S, Staurosporine; I, lndomethacin. 
* = different from previous period. 
4.5 Discussion 
The activation of PKC, elevation of intracellular calcium, and prostaglandin synthesis 
are major signal transduction pathways generated by phospholipase C and phosphotidyl-
inositol hydrolysis. The individual roles of each of these components and their complex 
interactions in regulating cell function is being extensively studied in different tissues. 
These intracellular messengers have also been shown to influence several signalling 
pathways and may be additive or antagonistic in their cellular response [355]. In the 
mammalian nephron, investigation of these pathways is of great interest because evidence 
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has linked them to the armediated inhibitory action on sodium and water transport, 
particularly in the distal segments. 
Ishikawa et al [356] showed that AVP increased intracellular free calcium 
concentration in rat papillary collecting tubule cultured cells, and this response was 
increased in the presence of a calcium-free medium. Other investigators have also 
demonstrated a coupling of the A VP response to intracellular and extracellular calcium 
levels [357, 358]. Other studies concluded that the increased cytosolic calcium occurs not 
by a direct inhibition of adenylyl cyclase via a Gi protein, but rather by A VP stimulation 
of PLC. PLC stimulation in turn activates PKC, which then inhibits cAMP formation in 
rat IMCD cells [341]. Similar results were obtained in the rabbit CCD [339, 359]. 
Studies in the isolated rat IMCD segments concluded that calcium increases m 
response to AVP are associated with the V2 receptor and are linked to adenylyl cyclase 
[338]. In contrast, studies in the isolated rat CCD have indicated the V1 receptor rather 
than the V2 receptor as mediating the intracellular calcium response [360]. In addition, 
calcium receptor proteins (CaRs) have now been reported in the rat IMCD [361]. These 
CaR.s sense and respond to alterations in extracellular calcium concentrations and 
specifically reduce A VP-induced osmotic water permeability when luminal calcium rises. 
Purified IMCD endosomes have been shown to contain aquaporin-2 [54], CaRs, specific 
stimulatory and inhibitory GTP binding proteins previously reported to interact with 
CaR.s [362], and isoforms of PKC [361]. Whether or not a CaR is located in the rat CCD 
is not yet known. 
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Dillingham et al [339] observed that a pronounced reduction in extracellular calcium 
concentration reduced the hydraulic conductivity (Lp) response of isolated rabbit CCDs 
to A VP and cAMP, and the addition of calcium ionophore A23187 had a stimulatory 
effect. Jones et al [340] investigated the effects of varying extracellular and intracellular 
calcium concentrations on the development of the hydrosmotic response of rabbit CCDs 
to A VP or cAMP. In that study, the investigators found that the A VP response was 
enhanced by lowering the extracellular calcium concentration from 1.0 to 0.1 mM, but was 
not altered by increasing it. Exposing the tubules to the lower calcium bath with the 
addition of the calcium chelator quin 2-AM inhibited the AVP response by 68%. 
Interestingly, .addition of the quin 2-AM after AVP enhanced the AVP response and 
addition of the calcium ionophore ionomycin decreased the A VP response. Those results 
are consistent with the view that transient changes in intracellular calcium levels are 
required for the development of the A VP response but that sustained increases inhibit the 
development and the maintenance of the A VP-induced hydrosmotic response. Although 
obtained under different experimental conditions and in a different species, these findings 
raise doubts about the specific role of intracellular and extracellular calcium concentrations 
in A VP-induced water permeability in the CCD. 
With this in mind, the present study was undertaken to determine the effect of 
decreased calcium concentrations on the ai-mediated inhibition of A VP-stimulated water 
transport in the rat CCD. Results indicate that transient decreased extracellular calcium 
concentrations do not affect A VP-induced water permeability (figure 2B) as compared to 
an AVP time-control study (figures 2A and 2C). This is in contrast with previous work 
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in the rabbit CCD [340] and in the rat medullary collecting tubule [363] where removal of 
calcium from the bath resulted in an increased A VP response while an increase in calcium 
was inhibitory. The inhibitory effect of extracellular calcium may be due to calcium 
influx into the cytosol where it increases the activity of cAMP-phosphodiesterase, and 
thus cAMP breakdown, while decreased calcium has the opposite effect where calcium 
moves out of the cytosol and thus decreases the activity of the cAMP-phosphodiesterase 
[363]. This response is species specific however, because increased cytosolic calcium 
concentrations and PKC activation do not inhibit water transport in the CCD of the rat 
[364]. Since the interest in the present study lies not with what calcium does to the AVP 
response so much as what influence calcium has on the Clz-mediated inhibition of the A VP 
response, the a.2 agonist dexmedetomidine was studied in the low calcium condition. 
Results indicate that dexmedetomidine is effective in inhibiting the A VP hydrosmotic 
response (figure 2D) and that a transient decrease in extracellular calcium does not limit 
the action of the a2 agonist (figures 2E and 2F). 
Gesek [353] showed that a2 receptors activate PLC and increase PKC activity in 
cultured distal convoluted tubule cells. Nadler et al [307] report that PGE2 reversibly 
inhibits AVP- and cAMP-stimulated Pr in the isolated rat IMCD and that 10 nM 
staurosporine prevents this inhibition. Ando et al [365] demonstrated that PKC 
activators suppress A VP-induced water transport at a step distal to cAMP generation in 
the rabbit CCD. Hebert et al [306] report that PGE2 inhibits A VP-induced water flow via 
PKC activation and Holt and Luchene [366] and Hebert et al [352] found that PGE2 
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inhibits sodium transport in the rabbit CCD. Rouch and Kudo [30] report that PKC and 
prostaglandins are involved in the a.2 mechanism, and that · staurosporine and 
indomethacin-sensitive cellular mediators modulate Pf in the rat IMCD, but Rouch et al 
[364] also concluded that intracellular calcium concentrations and PKC activation do not 
.inhibit sodium and water transport in the rat CCD. With those previous findings in mind, 
the goal of this part of the present study was to determine if intracellular prostaglandin 
production and PKC do indeed play a role in a.2-mediated inhibition, and if the respective 
pathways are independent of each other in the rat CCD. 
To test the involvement of prostaglandins and PKC, the cyclooxygenase inhibitor 
indomethacin was used at 5 µM the PKC inhibitor staurosporine was used at 10 nM. 
When used together, these inhibitors reversed dexmedetomidine-induced inhibition of 
A VP-stimulated water permeability (figure 3A). In addition, the a.2 inhibition returned 
upon removal of indomethacin and staurosporine from the bathing solution, indicating 
that the effects are reversible. Since it was not known whether one of these agents or both 
were required to cause this effect~ they were then examined separately. Indomethacin 
alone at 5µM and staurosporine alone at 10 nM failed to reverse dexmedetomidine's 
effects (figures 3B and 3C, respectively). Staurosporine at 100 nM was sufficient, 
however, to reverse the <Xi-mediated inhibition (figure 3D). These data suggest that PKC 
may be involved as part of a signalling pathway in the <Xi-mediated inhibition of A VP-
induced Pf in the rat CCD. In the final flux protocol, addition of the inhibitors was 
separated, with indomethacin being added to the bath a period before staurosporine. The 
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purpose of that protocol was to determine if the order of administration had an effect on 
the final outcome. Results do not indicate an order effect (figure 6). 
The application of electrophysiologic principles to the study of the collecting duct 
has been well studied and provide valuable information about sodium transport [5, 39, 42, 
367, 368]. The application of cable analysis to isolated, perfused tubules allows for the 
measurement oftransepithelial voltage and transepithelial resistance [346, 369]. In the rat 
CCD, AVP causes a sustained increase in sodium transport [2, 39, 142] thought to be the 
result of recruitment of epithelial sodium channels from cytoplasmic vesicles to the apical 
plasma membrane [45, 81, 146]. Increased sodium channel activity in the apical 
membrane depolarizes Vt, and decreases Rt [370]. 
The effect of increased intracellular calcium concentrations has been studied in the 
rabbit CCD where investigators found that it inhibits A VP-stimulated depolarization of 
Vt and decreases Rt [371, 372]. · The view of that study is that increased intracellular 
calcium concentrations reduce sodium transport by inhibiting the rate of sodium entry 
across the apical membrane [372]. To date, no other electrophysiolo~ical studies in the 
rat CCD have been done to determine if low extracellular calcium concentrations would 
effect the A VP-mediated response. Results of the present study indicate that decreased 
extracellular calcium does not effect sodium transport initiated by A VP (figures 4A and 
4B). Accordingly, results of the second electrophysiology study indicate that although 
there was an apparent reversal of the effects of dexmedetomidine with PKC and 
prostaglandin inhibition, the effect was statistically insignificant (figures 5A and 5B). The 
low n values as well as the high variability of these measurements make achieving 
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EFFECT OF OXYMETAZOLINE, ARC-239, AND WB4101 ON SODIUM AND 
WATER TRANSPORT IN THE RAT CCD 
5.1 Introduction 
Arginine vasopressin (A VP) stimulates water and sodium transport in the collecting 
duct of the rat and this response is inhibited by alpha-2 (a2) agonists. There are at least 
three subtypes of the a2 adrenoceptor ( a2A, UiB, and a2c), all of which are activated 
nonselectively by epinephrine and norepinephrine [233, 236-240]. One of these agonists 
is oxymetazoline, which has a binding preference for the a2A subtype [233, 237, 239, 
373]. There are currently no subtype-selective agonists for the a 2B, and a 2c subtypes, 
but antagonists that are a2 subtype-preferring are available. These include ARC-239, 
which has a high affinity for the a2B subtype [233, 237, 239, 373] and WB4101 which 
has a high affinity for the a 2c subtype [23 9, 3 73]. The inhibitory mechanism of the a2 
agonists is attributed to the reduction of intracellular cAMP through activation of an 
inhibitory G protein. Other studies have shown however, that a2 agonists inhibit water 
permeability even in the presence of nonhydrolyzable analogs of cAMP [29]. 
In order to characterize the response of the rat CCD to the a2A agonist 
oxymetazoline, flux experiments were performed to determine osmotic water permeability 
(Pr) and electrophysiological experiments were performed to determine transepithelial 
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voltage CVt) and transepithelial resistance (Rt) as an indicator of sodium transport. 
Electrophysiological experiments were conducted in controls, rats implanted with 
deoxycorticosterone (DOC) pellets, and rats fed a low salt diet. In the group fed a low 
salt diet, intracellular impalements were made to determine voltage across the basolateral 
membrane (V bl) and fractional resistance of the apical membrane (/Rap). Additional flux 
experiments were done using a nonhydrolyzable cAMP analog instead of A VP to 
stimulate transport in order to determine if cAMP is a required second messenger for the 
ai-mediated response. 
The a.28 antagonist ARC-23 9 and the a 2c antagonist WB4101 were also tested in flux 
studies where dexmedetomidine was used as the a 2 non-selective agonist in order to 
inhibit A VP-stimulated water permeability. 
5.2 Methods 
After dissection, CCDs were mounted on concentric pipettes and a control period 
was initiated as described previously (see chapter 3). AVP (220 pM) or 8CPTcAMP 
(100 µM) was used to stimulate Pr and either oxymetazoline (1 µM) or dexmedetomidine 
(1 µM) was used as the inhibitor. ARC-239 (1 µM) and WB4101 (1 µM) were used as 
~ antagonists. All agents were added to the bath and experiments were conducted at 37°C. 
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5.3 Source of Biochemicals 
AVP, 8CPTcAMP, ARC-239, and WB4101 were purchased from Sigma Chemical 
Co. (St. Louis, MO). Dexmedetomidine and atipamezole were obtained from Orion 
Pharma (Turku, Finland) and 3H-inulin was purchased from New England Nuclear 
(Boston, MA). 
5.4 Results 
5.4.1 Effect of Oxymetazoline on A VP- and cAMP-Stimulated P1 
Figure 7 shows that 1 µM oxymetazoline decreased A VP-stimulated Pf from 768±80 
to 194±35 µm/sec (p<.001) constituting an inhibition of 71 %. Atipamezole at 1 µM 
completely reversed the inhibition (p<.001) (figure 7A). In another protocol, 
oxymetazoline was added after the control period and Pf increased slightly, but not 
significantly, indicating that oxymetazoline does not effect basal Pf in the absence of 
AVP. Pf increased dramatically upon addition of AVP and atipamezole from 51±30 to 
507±92 µm/sec (p<.001) and was once again inhibited in the absence of atipamezole 
(p<.05) (figure 7B). Figure 7C shows that the non-hydrolyzable cAMP analog 8CPT-
cAMP increased Pf from 6±3 to 435±77 µm/sec (p<.001) and that oxymetazoline is 
unable to inhibit this (figure 7C). 
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5.4.2 Effect of Oxymetawline on Ve, Re, Vb1 and fRa 
Figure 8A shows that in control animals, oxymetazoline depolarized the A VP-
stimulated hyperpolarization in Vt from -8±1 to -7±1 mV (p < .01) and the effect was 
completely reversible. Oxymetazoline also inhibited the A VP-induced reduction in Rt, 
increasing it from 26±9 to 29±10 Q-cm2 (p<.05) (figure 8B). Figure 8C shows that 
oxymetazoline depolarized the A VP-stimulated hyperpolarization in Vt (p<.O 1) in DOC-
treated animals and the effect was again reversible. Oxymetazoline also inhibited the 
A VP-induced reduction in Rt in the DOC-treated group (p<.05) (figure 8D). Figure 8E 
shows that in animals fed a low salt diet for 4 or more days, oxymetazoline depolarized 
the AVP-stimulated hyperpolarization in Vt (p<.01) and inhibited the AVP-induced 
reduction in Rt (p<.05) (figure 8F). Principal cell impalements made on CCDs from low 
salt diet animals show that oxymetazoline inhibits Vb1 (figure 8G) and.fRap (figure 8H). 
Comparisons between the three groups (control, DOC-treated, low salt diet) in the 
electrophysiology studies shows that Vt was enhanced markedly in the DOC-treated and 
low salt diet groups (table IV). In the presence of AVP, there was a 38% increase in Vt in 
the control group (from -5.8±0.6 to -8.0±1.0 mV) and a 13% decrease with the addition of 
oxymetazoline (from -8.0±1.0to -7.0±1.0 mV). In the DOC-treated and low salt groups, 
the increases in Vt with A VP were 77% and 91 %, respectively (from -4.8±0.9 to -8.5±1.5 
and -4.5±1.3 to -8.6±1.9 mV). With the addition of oxymetazoline, Vt decreased by 32% 
and 21 %, respectively (from -8.5±1.5 to -5.8±1.0 and -8.6±1.9 to -6.8±1.8 mV). There 
was a 13% decrease in Rt in the control group in the presence of A VP (from 40.9±12.9 to 
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35.6±12.5 Q cm2) and an 11 % increase with the addition of oxymetazoline (from 
35.6±12.5 to 39.5±11.7 il·cm2). In the DOC-treated and low salt groups, the decreases in 
Rt with AVP were 12% and 25%, respectively (from 25.7±13.5 to 22.7±12.l and 
46.8±5.0 to 34.9±5.9 Q-cm2). With the addition of oxymetazoline, Rt increased by 13% 
and 24%, respectively (from 22.7±12.1 to 25.6±13.5 and 34.9±5.9 to 43.4±6.0 il·cm2). 
In the low salt group, V bl decreased and ./Rap increased with oxymetazoline and this effect 
was reversible. This data is summarized in table IV. 
Vt (mV) Control AVP AVP+Oxy AVP 
Control Diet -5.8±0.6 -8.0±1.0* -7.0±1.0* -8.0±1.0* 
Low Na Diet -4.5±1.3 -8.6±1.9* -6.8±1.8* -7.9±1.8 
DOC Pellet -4.8±0.9 -8.5±1.5* -5.8±1.0* -7.3±1.0* 
Rt (Q·cm2) Control AVP AVP+Oxy AVP 
Control Diet 40.9±12.9 35.6±12.5* 39.5±11.7* 36.3±11.4 
Low Na Diet 46.8±5.0 34.9±5.9* 43.4±6.0* 40.6±6.6 
DOC Pellet 25.7±13.5 22.7±12.1 * 25.6±13.5* 25.0±13.8 
Low Sodium AVP AVP+Oxy AVP 
I Vbl (mV) -86.0±1.4 -87.9±1.4* -86.6±0.9 n=4 
I /Rap .918+.020 .933+.017 .920±.020 n=4 
Table IV. Electrophysiological Data for Oxymetazoline. Summary for control, DOC-
treated, and rats fed a low sodium diet. See text for definitions. 
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Figure 7. Effects of oxymetazoline on AVP- and cAMP-stimulated Pr, (A) 
Oxymetazoline inhibits A VP-stimulated Pr. AVP stimulates Pr (p<.001) and 
oxymetazoline inhibits AVP-stimulated Pr (p<.001). Atipamezole reverses 
oxymetazoline inhibition (p<.001). n=lO. (B) Oxymetazoline does not effect 
basal Pr. Addition of AVP and atipamezole to the bath increases Pr (p<.001) 
and removal of atipamezole reduces Pr (p<.05). n=4. (C) Oxymetazoline 
does not affect cAMP-stimulated Pr, cAMP stimulates Pr (p<.001) and the 
addition of oxymetazoline and oxymetazoline + atipamezole have no effect. 
n=5. 
AVP, arginine vasopressin (220 pM); 0, 1 µM Oxymetazoline; A, 1 µM 
Atipamezole; cAMP, 100 µM 8-( 4-chlorophenylthio )-Cyclic Adenosine 
Monophosphate. 
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(B) 
Figure 8 (A and B). Electrophysiological effects of oxymetazoline. (A) 
Oxymetazoline depolarizes Vt in control rats. A VP hyperpolarizes Vt 
(p<.001) and addition of oxymetazoline to the bath depolarizes Vt (p<.05). 
This effect is reversed with removal of oxymetazoline (p<.05). (B) 
Oxymetazoline increases Rt in control rats. A VP reduces Rt (p<.05) and 
addition of oxymetazoline to the bath increases Rt (p<.05). n=4. 
t = different from control period. * = different from previous period. 
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(D) 
Figure 8 (C and D). Electrophysiological effects of oxymetazoline. (C) 
Oxymetazoline depolarizes Vt in low salt diet rats. A VP hyperpolarizes Vt 
(p<.001) and addition of oxymetazoline to the bath depolarizes Vt (p<.01). 
This effect is reversed with removal of oxymetazoline (p<.05). n=6. (D) 
Oxymetazoline increases Rt in low salt diet rats. AVP reduces Rt (p<.05) and 
addition of oxymetazoline to the bath increases Rt (p<.05). n=8. 
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(F) 
Figure 8 (E and F). Electrophysiological effects of oxymetazoline. (E) 
Oxymetazoline depolarizes Vb1 in low salt diet rats. Addition of 
oxymetazoline to the bath depolarizes Vb1 (p<.01) and this effect is reversed 
with removal of oxymetazoline (p<.05). n=4. (F) Oxymetazoline increases 
JRap in low salt diet rats. Addition of oxymetazoline to the bath increases }Rap 
and this effect is reversed with removal of oxymetazoline. n=5. 
t = different from initial A VP period. * = different from previous period. 
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(H) 
Figure 8 (G and H). Electrophysiological effects of oxymetazoline. (G) 
Oxymetazoline depolarizes Vt in DOC-treated rats. AVP hyperpolarizes Vt 
(p<.001) and addition of oxymetazoline to the bath depolarizes Vt (p<.001). 
This effect is reversed with removal of oxymetazoline (p<.05). n=5. (H) 
Oxymetazoline increases Rt in DOC-treated rats. AVP reduces Rt and 
addition of oxymetazoline to the bath increases Rt, n=4. 
t = different from control period. * = different from previous period. 
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5.4.3 Effect of ARC-239 on A VP-stimulated P1 
Figure 9 shows the results of the ARC-239 study. Dexmedetomidine at 1 µM 
inhibited A VP-stimulated Pf by 51 % (p<.05). ARC-239 reversed this inhibition by 39% 
(p<.05) (figure 9A). In another set of experiments, the experimental periods were 
reversed and ARC-239 still significantly blocked dexmedetomidine-mediated inhibition by 
50% (p<.05) (figure 9B). In both studies, there was no significant difference between the 













250 -!!! 400 
E 







Control AVP AVP+D AVP+D+ARC Control AVP AVP+D+ARC AVP+D 
(B) 
Figure 9. Effect of ARC-239 on dexmedetomidene-induced inhibition of Pf. 
(A) ARC-239 reverses dexmedetomide-induced inhibition of Pf. After the 
control period, 220 pM A VP was added to the bath and Pf increased 
(p<.001). Addition of 1 µM dexmedetomidine inhibited Pf and 1 µM ARC-
239 reversed the inhibition. n=4. (B) Effects of ARC-239 are reversible. 
n=4. 
AVP, arginine vasopressin; D, dexmedetomidine; ARC, ARC-239. 
t = different from control period. * = different from previous period. 
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. 5.4.4 Effect of WB41 OJ on A VP-stimulated P1 
Figure 10 shows the results of the WB4101 study. Dexmedetomidine at 1 µM 
inhibited AVP-stimulated Pr (p<.01) and WB4101 reversed this inhibition by 66% 
(p<.01) (figure lOA). In another set of experiments, the experimental periods were 
reversed and WB4101 still blocked dexmedetomidine-mediated inhibition by 65% (p<.01) 





















Control AVP AVP+D AVP+D+WB Control AVP AVP+D+WB AVP+D 
(B) 
Figure 10. Effect of WB4101 on dexmedetomidene-induced inhibition of Pf. 
(A) WB4101 reverses dexmedetomidine-induced inhibition of Pf. After the 
control period, 220 pM A VP was added to the bath and Pr increased 
(p<.001). Addition of 1 µM dexmedetomidine inhibited Pr and 1 µM 
WB4101 reversed the inhibition. n=5. (B) Effects of WB4101 are reversible. 
n=4. 
AVP, Arginine vasopressin; D, Dexmedetomidine; WB, WB4101. 
t = different from control period. * = different from previous period. 
5.5 Discussion 
The major findings of this study are that the a.2A-preferring agonist oxymetazoline 
inhibits A VP-stimulated Pr but not cAMP-stimulated Pr, and inhibits all of the measured 
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electrophysiological parameters. Overall these results suggest that oxymetazoline inhibits 
AVP-stimulated sodium and water reabsorption in the rat CCD via a cAMP-dependent 
mechanism. The finding that oxymetazoline alone did not affect Pf (figure 7B) supports 
previous studies indicating the requirement of AVP in the a2 effect [8]. 
It is known that a2 adrenergic receptors induce diuresis at two separate sites, one is 
AVP dependent while the other is non-A VP dependent [374, 375]. The A VP-dependent 
site occurs in the rat CCD and plays a critical role in the regulation of sodium and water 
balance [11, 47, 133, 141]. The effect of a2 agonists on sodium and water transport in 
the CCD has been extensively studied. Studies by Krothapalli et al [19, 20] indicate that 
the adrenergic-induced inhibition of A VP-stimulated Pf in the rabbit CCD occurs via a 
pre-cAMP event related to adenylyl cyclase inhibition. In 1984, Chabardes et al [376] 
showed that the a2 agonist clonidine reduces A VP-stimulated cellular cAMP increases in 
the rat CCD. Those findings were supported in 1985 by Umemura et al [160] who report 
that epinephrine inhibits A VP-stimulated cAMP accumulation in the rat CCD and IMCD 
and that the a2 antagonist yohimbine reverses the effects, suggesting an CXz-mediated 
mechanism. In 1991, Chen et al [6] showed that clonidine inhibited Pf and Vt, and in 1994 
Rouch and Kudo [7] showed that the a2 agonist dexmedetomidine inhibits Pf, Vt and Rt in 
the rat CCD. These findings were further supported by Rouch et al [8] when it was 
shown that the a2 antagonist atipamezole reverses those effects. 
Evidence suggesting that a signal pathway other than cAMP may be involved in the 
a 2 mechanism stemmed from a study by Hawk et al [29] in which the transport 
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properties of CCDs from Sprague-Dawley, Dahl salt-sensitive and salt-resistant rats were 
studied. In these studies rats were treated with DOC, which increases sodium 
reabsorption via mineralocorticoid actions, and epinephrine was found to inhibit A VP-
stimulated as well as cAMP-stimulated Pr, Therefore epinephrine inhibits both the 
cAMP-dependent flux produced by A VP and the cAMP-independent flux produced by 
DOC. They also showed that epinephrine inhibits Pr stimulated by the non-
hydrolyzable cAMP analog 8-bromo-adenosine, indicating that this inhibition occurs even 
in the presence of constant levels of intracellular cAMP. 
In the present study, the a.2A agonist oxymetazoline was studied in the isolated 
perfused rat CCD. Oxymetazoline significantly inhibited AVP-stimulated Pr (figure 7A) 
but did not inhibit Pr stimulated by the non-hydrolyzable cAMP analog 8CPT-cAMP 
(figure 7C). 8CPT-cAMP was used in this study because it is resistant to the actions of 
phosphodiesterase and because Snyder et al [18] showed that this analog is a potent 
activator of protein kinase A in CCD cells and suggested that it be the cAMP analog of 
choice in functional studies of isolated perfused tubules. 
The electrophysiological parameters of Vt, Rt, Vb1, and.fR.aP are used as an indicator of 
sodium transport, and figure 8 (A through H) illustrates that oxymetazoline inhibits the 
A VP-stimulated effects and is consistent with armediated inhibition of sodium 
reabsorption. Schafer and Troutman [ 40] showed that A VP increases sodium transport in 
the CCD by stimulating adenylyl cyclase and increasing cAMP levels. The increase in 
cAMP stimulates protein kinase A (PKA) and the subsequent phosphorylation of 
proteins leads to the insertion of sodium channels into the membrane from cytoplasmic 
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vesicles [146, 377]. In addition to AVP, aldosterone also increases sodium transport in 
the CCD, but this is thought to occur by a different mechanism. Aldosterone-stimulated 
sodium transport results from the opening of silent (cryptic) sodium channels already 
present in the membrane, protein synthesis of new sodium channels, and stimulation of 
the basolateral Na/K-ATPase [146, 148, 377]. Interestingly, oxymetazoline inhibited 
A VP-stimulated sodium transport even in DOC-treated rats and rats fed a low salt diet. 
Of further interest is the finding that while the DOC-treated and low salt diet rats had a 
more pronounced Vt response to both A VP and oxymetazoline (table IV), only the low 
salt group had an enhanced effect in R1• In impaled principal cells, Vb1 was 
hyperpolarized and .fRap increased in the presence of oxymetazoline and these effects 
were reversed when oxymetazoline was removed from the bathing solution (Table III). 
Wilborn et al [378] showed that the a2A adrenoceptor subtype is located in the 
cortical collecting duct of the rat, and concluded in 1998 [161] that the primary 
adrenoceptor involved in the regulation of sodium and water in the CCD is either an a2A 
or a2B based on isoform expression. Bylund et al [233] conducted an extensive study on 
the binding affinities of various drugs to a2A and a2B adrenergic receptor subtypes and 
determined that oxymetazoline binds with high affinity to the a2A subtype while ARC-
239 binds with highest affinity to the a2B subtype. In 1991, Uhlen et al [237, 373] 
supported those findings with binding studies showing a Kd (in nM) for oxymetazoline of 
13 at the a 2A receptor whereas the Kd at the a 2B receptor was 860 and the Kd was 120 at 
the a2c receptor, indicating a high selectivity of oxymetazoline for the a2A subtype. The 
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same set of studies also determined the Kd for ARC-239 to be 8.8 at the a28 receptor, and 
760 and 46 at the a2A and a2c receptors respectively. WB4101 was found to have a Kd 
of 4.5 at the a2c receptor with Kds of 140 and 26 at the a 2A and a28 receptors 
respectively [373]. 
In summary, this study indicates that the a2A subtype-preferring agonist 
oxymetazoline has an effect in the rat CCD where it inhibits A VP-stimulated salt and 
water reabsorption. In addition, these findings indicate that the intracellular signalling 
pathway of oxymetazoline is indeed coupled to the inhibition of adenylyl cyclase and 
thus inhibition of cAMP accumulation within the principal cell. In the present studies, 
the inhibition afforded by dexmedetomidine was an average of 67% and the inhibition by 
oxymetazoline was 60% which is not significantly different. This is of interest because 
dexmedetomidine is non-selective for the a2 subtype and has been shown to inhibit A VP-
stimulated Pf by cAMP inhibition and some other mechanism such as PKC inhibition as 
shown in the previous chapter (Chapter IV). This study also shows an effect with the 
a28 and a2c subtype-preferring antagonists in the rat CCD. ARC-239 reversed 
dexmedetomidine-induced inhibition by 45% and WB4101 reversed it by 66%. The non-
selective a.2 antagonist atipamezole reversed oxymetazoline-induced inhibition by 62%. 
This is of interest because all of the selected agents affected (inhibited or reversed 
inhibition) Pr by 60-67% except for ARC-239, which was less effective. It can not be 
suggested however, that ARC-239 is acting via a different receptor subtype than 
WB410 I or any other agents since all agents were used at the relatively high concentration 
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of 1 µM. Further experiments, including dose response studies, will need to be carried 
out in order to determine if these subtypes are truly functional in this nephron segment. 
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Chapter VI 
EFFECT OF AGMATINE ON WATER TRANSPORT 
IN THE RAT CCD 
6.1 Introduction 
Some of the biological effects previously thought to be mediated by a2 agonists are 
now known to be due to stimulation of a novel class of receptors called imidazoline 
receptors (I receptors or IR) [21, 379, 380]. These I receptors have a high preference for 
compounds with the imidazoline moiety such as clonidine and idazoxan [21, 246]. There 
are two main types of I receptors, 11 and 12. The 11 receptor has a higher affinity for 
clonidine and the 12 receptor has a higher affinity for idazoxan [246, 381]. Both subtypes 
have been shown that exist in the rat kidney [15, 16, 22, 382]. A number of differences 
have been demonstrated between ai-adrenergic receptors and I receptors in the rat 
kidney. Stimulation of either receptor leads to diuresis in the rat, but the increase after 
ai-adrenergic stimulation is secondary to free water clearance [383] whereas the increase 
after I 1 stimulation is secondary to an increase in osmolar clearance [380] indicating that 
salt and water excretion may or may not be coupled in the rat CCD. Free water clearance 
is movement of water that is not dependent on sodium transport, and is characteristic of 
the collecting duct. In addition, the effects of a2 stimulation are dependent on 
vasopressin while the effects of IR stimulation are not [380, 383]. Binding studies have 
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shown a 5-fold selectivity of idazoxan for 12 sites over a2 sites (Kct =10.6 vs. 55.4 nM, 
respectively) [384]. 
The endogenous ligand for these IRs remained a mystery until 1984 when a 
substance of unknown structure was isolated from human brain that bound with high 
affinity to imidazoline sites [260]. This substance was capable of displacing clonidine, 
which binds to a2 and I receptors and was thus called clonidine-displacing substance 
(CDS) [22]. In 1994, a CDS from bovine brain was isolated and its structure identified 
[261, 262]. It was determined to be a product of arginine metabolism and named 
agmatine. 
Arginine is metabolized to agmatine in the presence of arginine decarboxylase (ADC) 
[261,269,385]. Recent studies in the kidney have shown measurable agmatine levels and 
ADC activity, as well as diamine oxidase activity, an enzyme that metabolizes agmatine 
[269, 385]. Agmatine has been reported to bind with high affinity to a2, 11 and lz 
receptors making it the first endogenous imidazoline receptor ligand of known structure 
[261, 262]. Further studies have found that agmatine displays preferential affinity for the 
11 binding site [263-265]. In human platelets the affinity of agmatine for the 11 receptor 
subtype is 2200-fold greater than that of the 12 subtype, 1400-fold greater than that of the 
a 2A adrenoceptors, 5000-fold greater than the a 28 adrenoceptors, and 800-fold over the 
a 2c adrenoceptors [264]. 
Much research is being conducted in order to determine the physiological roles of 
agmatine. It is a cation and has been shown to open up some ion channels by activation 
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of nicotinic acetycholine receptors [271]. Agmatine may also have a role in insulin-
glucose metabolism since it was shown to facilitate the release of insulin from pancreatic 
cells exposed to glucose [272]. Functional studies of agmatine in the kidney have shown 
that in rats, microperfusion of agmatine into renal interstitium and the urinary space of 
the surface glomeruli produces reversible increases in the single nephron filtration rate 
(SNFR) and absolute proximal reabsorption (APR). Yohimbine (an a 2 antagonist) 
produces the opposite effects and BU-224 (an I2 agonist) mimics agmatine's effects on 
SNFR but does not effect APR [269]. Further studies show that agmatine's effects on 
SNFR can be blocked with N-monomethyl-arginine (NMMA), a nitric oxide synthase 
(NOS) inhibitor, and incubation of glomeruli with agmatine produces significant increases 
in cGMP formation which are not blocked with yohimbine [3 86]. Thus it remains unclear 
whether agmatine acts by binding to ai-adrenoceptors, imidazoline receptors, or by a 
separate mechanism. The purpose of this study was to determine the effect of agmatine on 
A VP-stimulated Pf in the rat CCD. The hypothesis is that agmatine will inhibit Pf in a 
manner not linked to a 2 adrenergic receptors. 
6.2 Methods 
After dissection, CCDs were mounted on concentric pipettes and a control period 
was initiated as described previously (see chapter 3). In one set of experiments, AVP 
(220 pM) was used to stimulate Pf, dexmedetomidine (1 µM) was used as the a 2 agonist, 
and idazoxan (1 µM) was used as the antagonist. In the other studies, A VP (220 pM) or 
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8CPTcAMP (100 µM) was used to stimulate Pr. In those experiments, agmatine, 
yohimbine, and idazoxan were all used at 1 µM. All agents were added to the bath and 
experiments were conducted at 37°C. The experimental protocols are shown in table V. 
Period 





Control AVP AVP+D AVP+D+I 
Control AVP AVP+Ag AVP 
Control AVP AVP+Ag AVP+Ag+Y 
Control cAMP cAMP+Ag cAMP+Ag+I 
Table V. Protocols to Investigate Agmatine. 
AVP, Arginine Vasopressin; Ag, Agmatine; cAMP, 8CPT-cAMP; D, 
Dexmedetomidine; I, Idazoxan; Y, Y ohimbine. 
6.3 Source of Biochemicals 
AVP and CPT-cAMP were purchased from Sigma Chemical Co. (St. Louis, MO). 
Idazoxan was purchased from Research Biochemicals International (Natick, MA). 
Agmatine sulfate was purchased from Tocris Cookson (Ballwin, MO). Yohimbine was 
kindly provided by Boehringer Ingelheim (Ridgefield, CT), and 3H-inulin was purchased 
from New England Nuclear (Boston, MA). 
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6.4 Results 
Figure 1 lA shows the results of protocol 1 using idazoxan with the a.2 adrenergic 
agonist dexmedetomidine. Dexmedetomidine inhibited AVP-stimulated Pr (p<.001) and 
this inhibition was reversed with idazoxan (p<.01). This blockade of a.2 effects was 
partial, reaching approximately 50% of maximal AVP stimulation (508±48 compared to 
252±48 µm/sec ). In protocol 2, A VP was used to stimulate Pr and agmatine inhibited this 
effect (figure l 1B) (p<.05). The removal of agmatine from the bath alowed Pr to increase 
again (p<.05) .. In protocol 3, the a.2 antagonist yohimbine failed to reverse the agmatine-
induced inhibition of AVP-stimulated Pr (figure 11C). In the fourth protocol, Pr was 
stimulated with 8CPT-cAMP and agmatine inhibited this effect (p<.05). The Ii and a.2 
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Figure 11. Effect of idazoxan and agmatine on Pr. (A) Idazoxan reverses 
dexmedetomidine-induced inhibition of Pr After the control period, 220 p M 
AVP was added to the bath and Pr increased (p<.001). Addition of 1 µM 
dexmedetomidine inhibited Pr (p<.001) and 1 µM idazoxan reversed the 
inhibition (p<.05). n=7. (B) Agmatine inhibits AVP-stimulated Pr. Agmatine 
(1 µM) inhibits AVP-stimulated Pr (p<.05) and the effect is reversible 
(p<.05). n=4. (C) Yohimbine does not reverse agmatine-induced inhibition of 
Pr. Agmatine inhibited A VP-stimulated Pr (p<.05) and yohimbine had no 
effect. n=4. (D) Agmatine inhibits cAMP-stimulated Pr and is not reversed 
with idazoxan. 100 µM cAMP stimulates Pr (p<.001) and agmatine inhibits 
this effect (p<.05). Idazoxan failed to reverse this inhibition. n=6. 
AVP, Arginine vasopressin; D, Dexmedetomidine; I, Idazoxan; Ag, Agmatine; 
Y, Yohimbine. 
t = different from control period. * = different from previous period. 
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6.5 Discussion 
One of the known effects of a2 adrenergic agonists is their ability to lower blood 
pressure centrally [247,248, 387]. This hypotensive effect is now accepted as being due 
to action on a 2 adrenergic receptors as well as nonadrenergic I receptors [387]. These I 
receptors are present in a range of mammalian tissues and are distinct from a2 receptors in 
that they are insensitive to the catacholamines epinephrine and norepinephrine [264, 
388]. The binding sites have been classified into two groups, 11 and Ii with the 12 subtype 
being preferential for idazoxan [270]. The Ii receptor has been suggested to play a role in 
protein activation in the brain, produce hyperalgesia in rats, and alter sodium uptake in 
rabbit kidney [384, 389, 390]. A number of studies indicate that 12 binding sites are 
associated with the monoamine oxidase system (MAO) enzymes [259, 391-394]. 
The substrate for the production of agmatine is arginine, which enters the cell by 
facilitated transport and is converted by the enzymatic action of ADC on the 
mitochondrial membrane [269] (see section 2.5.3 and diagram 7). Once synthesized, 
agmatine can bind to 12 receptors on the mitochondrion or to a2 adrenergic, and possibly 
I 1 receptors on the plasma membrane. It may also be released extracellularly since 
agmatine has been found in plasma. The synthesis of agmatine is thought to be regulated 
by feedback inhibition of ADC within the cell [270]. 
Although it was previously known to occur in plants, bacteria, and lower life forms, 
the discovery of ADC in rat brain indicates that the source of agmatine is endogenous 
since ADC is the enzyme involved in the rate-limiting step in agmatine biosynthesis. Of 
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additional interest is the localization of ADC to mitochondrial membranes since that is 
also the location ofI2 receptors [261]. Agmatine has been shown to be widely distributed 
in the body with its rank order of concentration being stomach > small intestine >> 
adrenal> heart> brain> plasma [262]. ADC activity has been identified in the renal 
cortex and medulla and diamine oxidase has been localized to the glomeruli [269], 
suggesting a functional role for agmatine in the kidney. 
The purpose of this study was two-fold. First, to test the effect of idazoxan on ar 
mediated inhibition of AVP-stimulated Pf in the rat CCD. Second, to determine if 
agmatine would have an effect on A VP-stimulated Pf in the rat CCD and if this effect was 
cAMP-mediated as well as whether or not it could be inhibited by a 2 or 12 receptor 
antagonists. With the first protocol, we found that dexmedetomidine inhibited A VP-
stimulated Pf by 81.3% and idazoxan reversed the inhibition by 32% (figure 1 lA). 
Agmatine inhibited A VP-stimulated Pf by 60% and inhibited cAMP-stimulated Pf by 
35%. Yohimbine reversed agmatine inhibition of AVP-stimulated Pf by only 4%, which 
was not significant and idazoxan failed to reverse agmatine inhibition of cAMP-mediated 
Pf(figures llC and llD, respectively). In summary, the key findings are that idazoxan 
can reverse armediated inhibition and this may occur through a 2 receptor antagonism or 
at a separate I receptor site, and that agmatine partially inhibits AVP- and cAMP-
stimulated Pf through a site distinct from the a 2 and Ii receptors. Agmatine may 
therefore represent a novel endogenous regulatory pathway for water reabsorption in the 
distal nephron. 
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The specific binding site for agmatine has not been identified, but Pinthong et al 
[395] found that while agmatine inhibits clonidine binding, it does not activate a.2 
receptors or inhibit a.rmediated responses in several rat tissues studied. Conversely, 
Molderings et al [396] report that in the rat vena cava, agmatine is a positive modulator at 
an allosteric a.2 binding site and an antagonist at the ligand recognition site of a.2 
adrenoceptors. In that study, agmatine increased clonidine affinity for a.radrenoceptors 
by 7 fold. It should be noted, however, that agmatine concentrations as high as 100 µM 
were required to initiate the effect. Interestingly, radioligand-labelled agmatine is not 
displaced by rauwolscine (a.2 antagonist), moxonidine (a.2 and I1 agonist), or cirazoline (a.1 
and Ii agonist) supporting the role of another receptor for agmatine. 
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Chapter VII 
EFFECT OF PEPTIDE YY ON A VP-STIMULATED SODIUM AND WATER 
TRANSPORT IN THE RAT CCD 
7.1 Introduction 
Peptide YY (PYY) is a member of the pancreatic polypeptide family and is released 
from the endocrine cells of the gut in response to food [273]. In humans, plasma levels of 
PYY increase postprandially and during diarrheal illness and cause a decrease in 
glomerular filtration rate (GFR), plasma renin activity, and aldosterone levels while 
increasing sodium excretion [13]. PYY shares 70% sequence homology with neuro-
peptide Y (NPY) and both bind with varied affinity to Y receptors (Yl - Y5) which have 
been identified in brain, heart, gut, blood vessels, and kidney of several species [285]. 
PYY and NPY bind with equal affinities to both the Yl and Y2 receptors and 
although most studies of PYY action have focused on the gastrointestinal system, Yl and 
Y2 receptors have been demonstrated in the kidney and shown to reduce renal blood flow 
(RBF) and lead to diuresis and natriuresis in the rat [14] [32]. Evidence suggests that the 
decrease in RBF is mediated via the Yl receptor whereas diuresis and natriuresis is 
mediated via the Y2 receptor [32]. Evidence also suggests that the Y2 receptor is coupled 
to a pertussis-toxin sensitive G protein and it has been proposed that NPY acts directly 
through an aradrenergic receptor in the rat CCD [26]. In the present studies, the specific 
Y2 receptor agonist PYY 3_36 was used to determine if the diuretic and natriuretic effects of 
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PYY are mediated by the Y2 receptor subtype in the rat CCD and yohimbine was used to 
determine if the effects are mediated by an alpha-2 mechanism. 
7.2 Methods 
After dissection, CCDs were mounted on concentric pipettes and a control period 
was initiated as described previously (see chapter 3). A VP (220 pM) was used to 
stimulate Pf and PYY 3_36 was used at 10 nM in one set of experiments and 100 nM in 
another set of experiments. All agents were added to the bath and experiments were 
conducted at 37°C. All rats were maintained on a low salt diet to maximize sodium 
transport. 
7.3 Source of Biochemicals 
AVP was purchased from Sigma Chemical Co. (St. Louis, MO). PYY3_36 was 
purchased from Peninsula Laboratories (CA) and idazoxan was purchased from Research 
Biochemicals International (Natick, MA). Y ohimbine was kindly provided by Boehringer 




7.4.1 Effect of PYY3_36 on A VP-Stimulated P1 
The data from the flux experiments show that in the rat CCD, Pr is near zero during 
the control period. With the addition of220 pM AVP, Pr increases from 4±1 to 499±59 
µm/sec in the first set of experiments, and the subsequent addition of PYY3•36 at 10 nM 
reduced Prto 392±66 µm/sec which is not a significant effect (figure 12A). In the second 
set of experiments, AVP increased Pr to 395±48 µm/sec and PYY3.36 at 100 nM 
significantly reduced AVP-stimulated Pr by 55.5% to 175±40 µm/sec (p<.05)(figure 
12B). In the third study, the a.2 adrenergic antagonist yohimbine was used at 1 µMin the 
final experimental period: In those experiments, 100 nM PYY 3.36 reduced Pr from 
484±50 to 311±22 µm/sec and yohimbine not only failed to reverse the PYY-mediated 
































Figure 12. Effect of 10 nM PYY3_36 on A VP-stimulated Pf. (A) 10 nM PYY3_36 
does not affect A VP-stimulated Pf. After the control period, 220 pM AVP 
was added to the bath and Pr increased (p<.001 ). Addition of 10 nM PYY3_36 
failed to significantly inhibit the AVP response. n=4. (B) 100 nM PYY3_36 
inhibits A VP-stimulated Pr (p<.001). n=5. (C) Effects of 100 nM PYY3_36 
are enhanced with 1 µM yohimbine. n=5. 
A VP, Arginine Vasopressin; PYY, PYY 3_36; Y, Y ohimbine. 
t = different from control period. * = different from previous period. 
7.4.2 Effect of PYY3_36 on V, and R, 
In the electrophysiology experiments, the initial control period Vt was -3.1±1.2 mV 
and this was hyperpolarized to -6.8±0.7 mV in the presence of AVP. Vt was inhibited by 
10 nM PYY3_36 to -5.5±0.8 mV (p<.05) (figure 13A). This effect was reversed when 
PYY3.36 was removed from the bathing solution and Vt hyperpolarized again to -7.1±0.5 
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mV (p<.05). Vt depolarized in the final control period to -5±1.0 mV (p<.05). The 
control Rt was 167±32-Q cm2 and was reduced with AVP to 130±20 O.cm2 (p<.05). 
PYY3_36 increased Rt to 142±19 Q-cm2 although this was not statistically significant. 
Removal of PYY3_36 from the bath decreased Rt to 133±18 Q-cm2 and returning to control 
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Figure 13. Electrophysiological effects of PYY3_36. (A) PYY3_36 depolarizes V1• 
After the control period, 220 pM A VP was added to the bath and Vt 
hyperpolarized (p<.001). Addition of PYY3_36 resulted in a depolarization 
(p<.05) that was reversible (p<.05). (B) PYY3_36 increases Rt. PYY3.36 
reversed the decrease in Rt irritated by A VP, but this was not statistically 
significant. n=8. 
t = different from control period. * = different from previous period. 
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7.5 Discussion 
The goal of this study was to determine if PYY acting through the Y 2 receptor would 
affect A VP-stimulated sodium and water permeability in the rat CCD. All Y receptor 
subtypes belong to the family of G protein-coupled receptors [275, 284]. They 
preferentially act through G0 or Gi and are therefore coupled to the inhibition of adenylyl 
cyclase [275]. Although other signalling pathways have been indicated, such as the 
mobilization of calcium secondary to IP3 production [397], renal Y2 receptors are believed 
to be negatively coupled to the cAMP pathway in the manner of a2 adrenergic receptors 
[278, 284, 290]. At the protein level, studies have identified Y receptor sites in rabbit 
kidney and identified them as predominantly of the Y2 subtype [290, 398, 399]. Few Y 
receptors have been detected in rat kidney by molecular biology techniques [14, 400], but 
this may be due to rapid radioligand degradation by endopeptidase-2 [401]. Functional 
experiments in isolated proximal tubules and isolated whole kidney however, have 
demonstrated that rat kidney does express Y receptors [33,277]. 
Wahlestedt et al [402] determined that Y1 receptors require the intact PYY or NPY 
molecule for binding while the Y2 receptor requires only the carboxyl terminal fragment of 
either peptide for binding. Competive binding experiments have shown differences 
between rabbit and rat Y receptor subtypes [13]. NPY competed effectively with 
radioactive PYY (1251-PYY) in both species, but the Y2 and Y4 agonists had no effect in 
the rat, and the Y1 agonist had no effect in the rabbit [13]. On the other hand, Sheikh et al 
[399] demonstrated that rabbit proximal tubule PYY receptors are of the Y2 subtype, and 
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Ohtomo et al [277] found the rat proximal tubule NPY receptors also to be of the Y2 
subtype. 
Previous studies show a Kd value for PYY in the rat papilla of 0. 7 nM which is only 
25 times the fasting concentration in rat plasma (28 pM) [403] and is consistent with 
receptor activation after postprandial increases of PYY. This Kd agrees with the value 
from binding studies of PYY in intestinal crypt cells [404], and thus supports a 
physiological role for PYY on renal receptors. There are two possible explanations for 
why PYY 3_36 at a concentration of 10 nM did not have an appreciable effect on water 
transport in the flux studies. First, it has been noted that PYY binds strongly to glass and 
the flux and electrophysiology experiments utilize solution reservoirs made of glass as 
well as glass pipettes suspending the tubules. It is therefore possible that the PYY3_36 
concentration delivered to the tubule was much less than the original 10 nM. Second, it 
has been shown that the closely related peptide, NPY, is more effective in vivo than in 
vitro [276]. This may be due to the presence of tonic adrenergic and/or other stimuli in 
vivo, and the absence of such stimuli in vitro. Increasing the PYY3_36 concentration to 100 
nM did have a significant effect on the isolated rat CCD, however the exact delivered 
concentration was not determined. 
Infusion of PYY or NPY causes a reduction in renal blood flow [31] and thus it could 
be expected that PYY would inhibit sodium and water excretion. Studies in anaesthetized 
rats however, have reported an increase in urine flow after NPY administration [25, 31]. 
Diuresis has also been reported in humans after administration of PYY doses 
corresponding to physiological postprandial plasma levels [405]. Studies by Blaze et al 
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[13] and Bischoff et al [31] concluded that physiologic doses of NPY and PYY are 
natriuretic. This supports the present studies which demonstrate that PYY3_36 is capable 
of hyperpolarizing transepithelial voltage and increasing transepithelial resistance in the 
principal cell (figures 13A and 13B) although the effects on Rt were not statistically 
significant. This Vt data is in accordance with the flux data presented in the current study 
showing that A VP-induced water permeability is inhibited with PYY3_36 (figure 12B). 
In renal vasculature, PYY and NPY have been shown to potentiate the 
vasoconstricting effects of other drugs [275, 276, 282, 406, 407]. Indeed, NPY has been 
shown to be stored and released with norepinephrine from sympathetic nerves [27 4]. 
Pemow and Lundberg [282] found that NPY and a 2 agonists inhibit norepinephrine 
release in parallel, and the a 2 antagonist yohimbine enhances NPY and norepinephrine 
-
release, indicating an a 2-mediated inhibition of release in pig sympathetic neurons. 
Interestingly, the present study indicated that yohimbine enhanced PYY-mediated 
inhibition of A VP-stimulated Pi (figure 12C). This is in contrast the study by Dillingham 
and Anderson [26] in which the authors concluded that NPY actions occur via an a 2 
receptor in the rat CCD. In addition, Harfstrand and Fuxe [408] report that the 
hypotensive effect of NPY is enhanced after central blockade of the aradrenoceptor 
using idazoxan in rat brain. Although the relationship between aradrenergic receptors 
and Y receptors is still unclear, receptor interaction may exist at the coupling unit and/or 
at the recognition site proteins. In conclusion, the present study shows that PYY inhibits 
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AVP-stimulated water and salt transport through the Y2 receptor subtype m a manner 
that may be infuenced by a2 adrenergic receptors in the rat CCD. 
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Chapter VIII 
SUMMARY AND CONCLUSIONS 
The data obtained in these studies leads to the following conclusions concerning 
sodium and water transport in the isolated, perfused rat CCD: 
1. Decreased extracellular and luminal calcium concentrations do not affect A VP-
stimulated Pf, Vt, or Rt, or armediated inhibition of A VP-stimulated Pf. 
2. PKC inhibition reverses armediated inhibition of A VP-stimulated Pf. 
3. The a 2A-preferring agonist oxymetazoline inhibits AVP- but not cAMP-
stimulated Pf, depolarizes Vt, and increases Rt in rats fed normal or low salt 
diets, and in rats treated with DOC. 
4. The a 28-preferring antagonist ARC-239 reverses armediated inhibition of 
A VP-stimulated Pf, 
5. The a 2c-preferring antagonist WB4101 reverses armediated inhibition of 
A VP-stimulated Pf. 
6. The ar and Ii-preferring antagonist idazoxan reverses armediated inhibition of 
AVP-stimulated Pf, 
7. Agmatine, the putative endogenous imidazoline ligand, inhibits A VP- and 
cAMP-stimulated Pf and is not reversed with ai- or Ir receptor antagonists. 
8. The Yz-preferring agonist PYY3•36 inhibits A VP-stimulated Pf, depolarizes Vt 
and increases Rt, 
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The mechanism of A VP stimulated water and sodium permeability in the principal 
cell of the CCD occurs through the activation of a V 2 adrenergic receptor coupled to a 
stimulatory G protein that activates adenylyl cyclase and leads to an increase in 
intracellular cAMP levels. The mechanism of a.2 adrenergic inhibition of A VP-stimulated 
permeability involves inhibition of the cAMP increase through the a.2 adrenergic receptor 
coupled to an inhibitory G protein. The discovery in 1993 by Hawk et al [29] showing 
that another signalling pathway is also present has lead to much interest in second 
messengers and receptor subtypes. Studies investigating second messengers have already 
shown that a.2 adrenergic receptors activate PLC and increase PKC activity in cultured 
distal convoluted tubule cells [353] and that PGE2 reversibly inhibits AVP- and cAMP-
stimulated Pr in the isolated rat IMCD [307]. Those reports raised the question of 
whether or not a.2 adrenergic receptors in the rat CCD rely on the PLC/PKC pathway or 
generation of prostaglandins in addition to cAMP inhibition to produce their inhibitory 
effect on A VP-stimulated salt and water permeability. 
The present investigations conclude that extracellular calcium and intracellular 
prostaglandin production are not required for the inhibitory effect of the a.2 adrenergic 
receptors. Furthermore, PKC is indicated as a second messenger involved in the a.2 
inhibition of AVP-stimulated water permeability in the rat CCD. Of additional 
importance is the finding that oxymetazoline inhibits AVP-stimulated, but not cAMP-
stimulated water permeability, from which it is concluded that the a.2A -subtype relies on 
inhibition of adenylyl cyclase as its mode of action. It is further concluded that agmatine 
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inhibits A VP-stimulated water permeability in the rat CCD via a receptor distinct from 
aradrenergic and i'midazoline receptors. Finally, it is concluded that PYY inhibits A VP-
stimulated salt and water permeability in the rat CCD not through an a 2 receptor, but 
through a Y2 receptor that may be influenced or coupled to the a 2 receptor. 
All of the above conclusions constitute a basis for future studies. These studies were 
designed to provide new information on the possible signalling pathways and second 
messengers involved in the armediated mechanism of inhibition, and to provide some 
insight to the actions of agmatine and PYY as they relate to armediated inhibition of salt 
and water permeability in the rat CCD. Certainly more in-depth investigation is required, 
including establishment of dose-response curves and assays for specific second 
messengers. Utilization of other techniques such as immunohistochemistry to visualize 
specific receptors, and patch-clamping to characterize ion movement will be needed to 
provide a better understanding of the armediated mechanism. It is also important to 
remember that these studies have been carried out in vitro, without the many possible 
influences from other endogenous neurotransmitters and hormones. 
In the CCD in vivo, circulating A VP and aldosterone lead to increased reabsorption 
of sodium and water by the principal cell while epinephrine and norepinephrine 
counteract this effect through the a 2 adrenergic receptor. Renal dopamine produced in the 
proximal tubule binds to luminal receptors in the CCD and acts to inhibit AVP-induced 
sodium and water permeability. Renal serotonin is also produced by proximal tubule cells 
but has the opposite effect as dopamine in that it promotes natriuresis and diuresis. ANP 
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influences CCD function by modulating renin and aldosterone secretion, and may have a 
direct stimulatory effect on sodium and water excretion in the principal cell. Another 
natriuretic hormone, urodilatin, is synthesized in the kidney and its effect on the principal 
cell is still unknown. Endothelin produced in the kidney acts as a tonic modulator of 
sodium transport and has yet undetermined effects in the CCD. These hormones and 
other endocrine, neurocrine, and paracrine substances that regulate principal cell sodium 
and water permeability dictate an appreciation for the complexity of renal sodium and 
water homeostasis. Dissecting individual signalling pathways and receptor interactions is 
required to better understand these mechanisms and ultimately lead to improved 
treatments for hypertension and diseases of sodium imbalance. 
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IR, a 2-AR 
IR1 
IR2 
a 2A-AR, IR 
a 2-AR, IR 
IR1 
a 2-AR, IR1 
a 2-AR, IR 
a 2-AR, IR 
a 1-AR, a 2-AR 




a 2-AR, IR 
a 2A-AR 
a 1-AR 
a 2-AR, IR1 
a 2-AR, IR 
a2B-AR 





a 2-AR, IR1 
a 2-AR, IR2 
a 1-AR 
a 1-AR, a 2-AR, IR 





a 1-AR, a 2-AR, IR 




a2A=I1> a2c>> a2B >>I2 
a2A>I1>>I2 
I2> a2A >>I1 
I1 - clonidine preference, plasma membrane bound and G protein mediated 
~ - cirazoline and idazoxan preference, mitochondrial bound and MAO mediated 
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Appendix C - Experimental Drugs 
Agmatine (Agm) Stock solution 2.28 mg Agm per ml water 
Use 1 µl in 10 mls bath for 1 µM 
Amiloride (Amil) 0.27 mg in 100 mls control bath solution 
May need to sonicate to dissolve 
Filter before using 
Arginine Vasopressin (AVP) Stock solution: 100 µl AVP in 9.89 mls water 
Use 1 µl per ml bath for 220 pM 
Make new stock solution every 2 weeks 
Atipamizole (Ati) Stock solution: 3.1 mg Ati per ml water 
Use 1 µl in 100 mls bath for 100 nM 
Use 1 µl in 10 mls bath for 1 µM 
cAMP (8-CPT-cAMP) Stock solution: 100 mg cAMP in 10 mls 
water 
Use 750 µl in 150 mls bath for 100 µM 
Aliquot and freeze with dessicant 
Dexmedetomidine (Dex) Stock solution: 2.95 mg Dex per ml water 
Use 1 µl in 100 mls bath for 100 nM 
Use 1 µl in 10 mls bath for 1 µM 
Idazoxan (Ida) Stock solution: 1 mg Ida per ml water 
Use 12 µl in 50 mls bath 
Indomethacin (lndo) Stock solution: 1.8 mg Indo per ml water 
Use 1 µl per ml bath for 5µM 
Oxymetazoline (Oxy) Stock solution: 2.97 mg Oxy per ml water 
Use 1 µl in 10 mls bath for lµM 
Peptide YY3_36 (PYY3_36) Stock solution: 2.5 mls water in 0.5 mg vial 
Aliquot and freeze 92 µl per vial 
Use 1 vial per 50 mls bath for 100 nM 
Staurosporine (ST) Stock solution: 100 mg SSP in 1 ml water 
Aliquot and freeze 100 µl per vial 
Use 1 vial per 200 mls bath for 1 µM 
WB 4101 (WB) Stock solution: 50 mg WB in 6.58 mls water 
Aliquot and freeze 5 µl per vial 
Use 5 µl in 100 mls bath for 1 µM 
Y ohimbine (Yoh) HCl Stock solution: 9 .8 mg Yoh in 25 mls water 
Aliquot and freeze 100 µl per vial 
Use 1 vial per 100 mls bath for 1 µM 
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Appendix D - Data Tables and Statistics 
Chapter IV - Figure lA 
Raw Data: 
Experiment #1 #2 
Control 3.0000 4.0000 
AVP 176.00 272.00 
AVP2 133.00 143.00 



































d f Sum of Squares Mean Square 
3 218976.688 72992.229 
3 186692.688 62230.896 
9 79517.063 8835.229 












F-Value P-Value G-G H-F 
7.043 .0098 .0643 .0477 
t-Test P-Value 
-4.427 .0017 




































































Mean Std. Dev. Std. Error 
1.000 1 .155 .577 
269.750 60.390 30.195 
229.500 85.590 42.795 
249.250 63. 788 31.894 
11.500 12.871 6.436 
df Sum of Squares Mean Square F-Value P-Value G-G H-F 
3 15458.000 5152.667 
4 287479.700 71869.925 28.588 .0001 .0019 .0001 
1 2 30167.500 2513.958 
Diff. Std. Error t-Test P-Value 
-268. 750 35.454 -7 .580 .0001 
-228.500 35.454 -6.445 .0001 
-248.250 35.454 -7 .002 .0001 
-10.500 35.454 -.296 .7722 
40.250 35.454 1 .135 .2784 
20.500 35.454 .578 .5738 
258.250 35.454 7.284 .0001 
-19.750 35.454 -.557 .5877 
218.000 35.454 6.149 .0001 
237.750 35.454 6.706 .0001 
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F-Value P-Value G-G H-F 











































avp LC avp+dex 
avp2 



























































F-Value P-Value G-G H-F 
























































Type Ill Sums of Squares 
Source df Sum of Squares Mean Square F-Value P-Value G-G H-F 
Subject 2 
condition 3 
condition * Subject 6 
. . .. 

















374560.917 124853.639 6.493 .0259 .0690 .0259 
115365.833 19227 .639 
Std. Error t-Test P-Value 
113.218 -2.850 .0292 
113.218 .029 .9775 
113.218 1.446 .1984 
113.218 2.879 .0281 
113.218 4.296 .0051 
113.218 1 .416 .2065 
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df Sum of Squares Mean Square 
3 130156.400 43385.467 
4 510903.800 127725.950 
1 2 112570.600 9380.883 
























F-Value P-Value G-G H-F 





































































di Sum of Squares 
3 58493.400 
4 651291.700 


























































F-Value P-Value G-G H-F 











-1. 198 .2542 















































df Sum of Squares 
3 89801. 688 









































F-Value P-Value G-G H-F 
16.607 .0005 .0046 .0005 






















































di Sum of Squares 
4 7079.300 
3 171159.750 













































F-Value P-Value G-G H-F 
55.215 .0001 .0001 .0001 
t-Test P-Value 
-12.277 .0001 






































































di Sum of Squares Mean Square F-Value P-Value G-G H-F 
4 24.825 6.206 
3 6.438 2.146 2.901 .0787 .1553 .1466 
1 2 8.875 .740 
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df Sum of Squares Mean Square F-Value P-Value G-G H-F 
4 17725.000 4431.250 
3 1433.350 477.783 3.607 .0459 .1014 .0724 
12 1589.400 132.450 
Diff. Std. Error t-Test P-Value 
16.400 7.279 2.253 .0437 
17.800 7.279 2.445 .0308 
22.400 7.279 3.077 .0096 
1.400 7.279 .192 .8507 
6.000 7.279 .824 .4258 
4.600 7.279 .632 .5393 
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d f Sum of Squares 
4 177 .650 
4 119.658 
#3 #4 #5 
2.00 0.00 0.00 
-5.00 -10.0 -5.00 
-2.00 -7.00 -3.00 
-2.00 -6.00 -4.00 
-2.00 -4.00 -3.00 






Mean Square F-Value P-Value G-G H-F 
44.412 
29.914 12.480 .0001 .0165 .0107 




Vs. Diff. Std. Error t-Test P-Value 
Control AVP 6.800 .979 6.945 .0001 
AVP+Dex 4.000 .979 4.085 .0009 
AVP+Dex+l+St 4.040 .979 4.126 .0008 
AVP+Dex2 2.980 .979 3.043 .0077 
AVP AVP+Dex -2.800 .979 -2.860 .0114 
AVP+Dex+l+St -2. 760 .979 -2.819 .0124 
AVP+Dex2 -3.820 .979 -3.901 .0013 
AVP+Dex AVP+Dex+l+St .040 .979 .041 .9679 
AVP+Dex2 -1.020 .979 -1.042 .3130 
AVP+Dex+l+St AVP+Dex2 -1.060 .979 -1.083 .2951 
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conditions * Subject 










AVP+Dex A VP+Dex+l+S 
AVP+Dex2 
AVP+Dex+l+S AVP+Dex2 
#2 #3 #4 #5 
16.80 34.80 25.30 18.20 
12.40 30.20 20.30 16.00 
25.10 33.30 25.60 17.60 
19.80 32.00 25.20 16.80 
28.90 34.10 29.40 19.80 
Mean Std. Dev. Std. Error 
29.140 13.958 6.242 
24.200 12.022 5.376 
29.940 11.572 5.175 
28.380 12 .448 5.567 
33.180 12.585 5.628 
di Sum of Squares Mean Square F-Va\ue P-Va\ue G-G H-F 
4 3047.638 761.910 
4 208.974 52.244 8.469 .0007 .0252 .0127 
1 6 98.702 6.169 
Diff. Std. Error t-Test P-Value 
4.940 1.571 3.145 .0063 
-.800 1.571 -.509 .6175 
.760 1.571 .484 .6351 
-4.040 1.571 -2.572 .0205 
-5.740 1.571 -3.654 .0021 
-4.180 1.571 -2.661 .0171 
-8.980 1'.571 -5.717 .0001 
1.560 1.571 .993 .3354 
-3.240 1.571 -2.063 .0558 
-4.800 1 .571 -3.056 .0075 
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#2 #3 #4 #5 #6 #7 #8 
211.0 193.0 155.0 354.0 374.0 202.0 320.0 
313.0 354.0 183.0 250.0 291.0 124.0 365.0 
219.0 345.0 320.0 229.0 73.00 37.00 159.0 
105.0 388.0 226.0 165.0 73.00 11.00 159.0 
Mean Std. Dev. Std. Error 
249.500 85.489 30.225 
276.000 85.132 30.099 
175.375 124.324 43.955 
144.375 122.260 43.225 
di Sum of Squares Mean Square F-Value P-Value G-G H-F 
7 135271.375 19324.482 
3 91319.125 30439.708 3.562 .0316 .0699 .0545 
21 179446.375 8545.065 
Diff. Std. Error t-Test P-Value 
-26.500 46.220 -.573 .5725 
74.125 46.220 1.604 .1237 
105.125 46.220 2.274 .0335 
100.625 46.220 2.177 .0410 
131.625 46.220 2.848 .0096 
31.000 46.220 .671 .5097 
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#2 #3 #4 #5 
2.0000 2.0000 0.0000 5.0000 
584.00 820.00 484.00 734.00 
239.00 258.00 223.00 27.000 
1280.0 1010.0 408.00 674.00 
#7 #8 #9 #10 
1.0000 14.000 7.0000 1.0000 
727.00 962.00 1073.0 304.00 
206.00 284.00 0.0000 101.00 
574.00 604.00 782.00 426.00 
Mean Std. Dev. Std. Error 
5.400 5.400 1.707 
677.700 251.404 79.501 
193.900 111.617 35.296 
738.700 307.043 97.095 
d f Sum of Squares Mean Square F-Value P-Value G-G H-F 
9 510994.525 56777 .169 
3 3899597 .275 1299865. 758 34.452 .0001 .0001 .0001 
27 1018702.975 37729.740 
Diff. Std. Error t-Test P-Value 
-672.300 86.867 -7. 739 .0001 
-188.500 86.867 -2.170 .0390 
-733.300 86.867 -8.442 .0001 
483.800 86.867 5.569 .0001 
-61.000 86.867 -. 702 .4886 
-544.800 86.867 -6.272 .0001 
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Oxy Oxy+A VP+Ati 
Oxy+AVP 






















































F-Value P-Value G-G H-F 
14.185 .0009 .0051 .0009 
t-Test P-Value 
-.468 .6512 






































Type Ill Sums of Squares 
Source df Sum of Squares 
Subject 4 211225.200 
condition 3 654285.200 





Control cAMP -428.800 
cAMP+Oxy -401.400 
cAMP+Oxy+Ati -421.000 
cAMP cAMP+Oxy 27.400 
cAMP+Oxy+Ati 7.800 






































F-Value P-Value G-G H-F 







-.325 . 7511 





















































Mean Std. Dev. Std. Error 
-5.875 .854 .427 
-9.000 2.449 1.225 
-7.250 1.500 .750 
-8.750 2.062 1 .031 
df Sum of Squares Mean Square F-Value P-Value G-G H-F 
3 31. 797 10.599 
3 25.297 8.432 9.618 .0036 .0456 .0354 
9 7.891 .877 
Diff. Std. Error t-Test P-Value 
3.125 .662 4.720 .0011 
1.375 .662 2.077 .0676 
2.875 .662 4.342 .0019 
-1.750 .662 -2.643 .0268 
-.250 .662 -.378 .7145 
1.500 .662 2.266 .0497 
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Mean Std. Dev. Std. Error 
42.725 15.842 7.921 
35.425 13.860 6.930 
40.525 14.224 7.112 
37.400 16.106 8.053 
di Sum of Squares Mean Square F-Value P-Value G-G H-F 
3 2664.757 888.252 
3 126.162 42.054 7.627 .0077 .0269 .0077 
9 49.626 5.514 
Diff. Std. Error t-Test P-Value 
7.300 1.660 4.396 .0017 
2.200 1.660 1.325 .2178 
5.325 1.660 3.207 .0107 
-5.100 1.660 -3.072 .0133 
-1.975 1.660 -1.189 .2647 
3.125 1.660 1.882 .0925 
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df Sum of Squares Mean Square F-Value P-Value G-G H-F 
5 474.375 94.875 
3 75.458 25.153 15.858 .0001 .0022 .0004 
15 23.792 1.586 
Diff. Std. Error t-Test P-Value 
4.833 .727 6.647 .0001 
3.167 .727 4.355 .0006 
3.500 .727 4.814 .0002 
-1.667 .727 -2.292 .0368 
-1.333 .727 -1.834 .0866 
.333 .727 .458 .6532 
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#2 #3 #4 #5 #6 #7 #8 
62.0 51.0 52.0 23.0 62.0 52.0 31.0 
58.0 40.0 13.0 19.0 51.0 47.0 19.0 
60.0 45.0 55.0 23.0 59.0 55.0 17.0 
51.0 44.0 29.0 19.0 59.0 55.0 16.0 
Mean Std. Dev. Std. Error 
46.750 14.059 4.970 
34.875 16. 728 5.914 
43.375 16.953 5.994 
36.875 17.349 6.134 
di Sum of Squares Mean Square F-Value P-Value G-G H-F 
7 6426.219 918.031 
3 736.844 245.615 4.984 .0091 .0313 .0199 
21 1034.906 49.281 
Diff. Std. Error t-Test P-Value 
11.875 3.510 3.383 .0028 
3.375 3.510 .962 .3472 
9.875 3.510 2.813 .0104 
-8.500 3.510 -2.422 .0246 
-2.000 3.510 -.570 .5749 
6.500 3.510 1.852 .0782 
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F-Value P-Value G-G H-F 



































































F-Value P-Value G-G H-F 
4.090 .0598 .0643 .0598 


























































Mean Std. Dev. Std. Error 
-4.600 1.517 .678 
-8.200 2.683 1.200 
-5.800 1. 789 .800 
-7.200 1.789 .800 
di Sum of Squares Mean Square F-Value P-Value G-G H-F 
4 54.200 13.550 
3 37.350 12.450 15.894 .0002 .0062 .0018 
12 9.400 .783 
Diff. Std. Error t-Test P-Value 
3.600 .560 6.431 .0001 
1.200 .560 2.144 .0532 
2.600 .560 4.645 .0006 
-2.400 .560 -4.288 .0011 
-1.000 .560 -1.786 .0993 
1.400 .560 2.501 .0279 
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Mean Std. Dev. Std. Error 
28.550 19.959 9.980 
26.325 18.575 9.287 
28.825 20.206 10.103 
28.125 20.489 10.244 
di Sum of Squares Mean Square F-Value P-Value G-G H-F 
3 4700.367 1566. 789 
3 15 .187 5.062 3.267 .0732 .1586 .1435 
9 13.946 1.550 
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di Sum of Squares Mean Square F-Value P-Value G-G H-F 
3 39297.500 13099.167 
3 223283.500 74427.833 26.426 .0001 .0020 .0001 
9 25348.000 2816.444 
Diff. Std. Error t-Test P-Value 
-312.500 37.526 -8.327 .0001 
-149.250 37.526 -3.977 .0032 
-250.250 37.526 -6.669 .0001 
163.250 37.526 4.350 .0018 
62.250 37.526 1.659 .1315 
-101.000 37.526 -2.691 .0247 
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di Sum of Squares Mean Square F-Value P-Value G-G H-F 
3 65702. 750 21900.917 
3 737281.250 245760.417 26.186 .0001 .0030 .0001 
9 84465. 750 9385.083 
Diff. Std. Error t-Test P-Value 
-562.250 68.502 -8.208 .0001 
-431.750 68.502 -6.303 .0001 
-209.500 68.502 -3.058 .0136 
130.500 68.502 1.905 .0892 
352.750 68.502 5.149 .0006 
222.250 68.502 3.244 .0101 
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Type Ill Sums of Squares 
Source di Sum of Squares Mean Square 
Subject 4 63984.500 15996.125 
condition 3 837303.600 279101.200 




Vs. Diff. Std. Error 
control AVP -521.000 57.902 
AVP+Dex -123.000 57.902 
AVP+dex+WB4101 -374.400 57.902 
AVP AVP+Dex 398.000 57.902 
AVP+dex+WB4101 146.600 57.902 

















F-Value P-Value G-G H-F 
33.299 .0001 .0007 .0001 
t-Test P-Value 
-8.998 .0001 












































































85. 732 42.866 
90.644 45.322 
Mean Square F-Value P-Value G-G H-F 
9185.500 
285758.167 119.055 .0001 .0010 .0004 
2400.222 
Std. Error t-Test P-Value 
34.643 -17.442 .0001 
34.643 -10.204 .0001 
34.643 -3.442 .0074 
34.643 7.238 .0001 
34.643 14.000 .0001 
34.643 6.762 .0001 

































#2 #3 #4 #5 #6 #7 
3.000 3.000 14.00 9.000 15.00 35.00 
346.0 627.0 444.0 495.0 705.0 548.0 
55.00 97.00 221.0 19.00 251.0 0.000 
99.00 170.0 282.0 460.0 348.0 140.0 
Mean Std. Dev. · Std. Error 
14.857 11. 725 4.432 
508.429 127.850 48.323 
92.000 104.395 39.458 
252.286 126.676 47.879 
d I Sum of Squares Mean Square F-Value P-Value G-G H-F 
6 103281.429 17213.571 
3 998636.679 332878.893 38.094 .0001 .0001 .0001 
18 157288.571 8738.254 
Diff. Std. Error t-Test P-Value 
-493.571 49.966 -9.878 .0001 
-77.143 49.966 -1.544 .1400 
-237.429 49.966 -4. 752 .0002 
416.429 49.966 8.334 .0001 
256.143 49.966 5.126 .0001 
-160.286 49.966 -3.208 .0049 
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Mean Std. Dev. Std. Error 
2.250 3.304 1.652 
362.750 66.515 33.258 
135.750 70.035 35.018 
234.750 63.063 31.531 
di Sum of Squares Mean Square F-Value P-Value G-G H-F 
3 6971.250 2323.750 
3 279552.750 93184.250 25.429 .0001 .0089 .0035 
9 32979.750 3664.417 
Diff. Std. Error t-Te$t P-Value 
-360.500 42.804 -8.422 .0001 
-133.500 42.804 -3. 119 .0123 
-232.500 42.804 -5.432 .0004 
227.000 42.804 5.303 .0005 
128.000 42.804 2.990 .0152 
-99.000 42.804 -2.313 .0460 
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condition • Subject 


































































F-Value P-Value G-G H-F 

































































df Sum of Squares 
5 90970.875 
3 310241.458 
1 5 82128.292 




























Mean Square F-Value P-V... G-G H-F 
18194.175 




















































Type Ill Sums of Squares 
Source df Sum ofSquares Mean Squa ... 
condition 3 635819.250 211939.75 
Residual 12 164314.500 13692.875 
Dependent: conditions 
Contrasts: 
Vs. Diff. Std. Error 
control avp -494.250 82.743 
avp+pyy -387.750 82.743 
avp2 -471.500 82.743 
avp avp+pyy 106.500 82.743 
avp2 22.750 82.743 























































































df Sum of Squares Mean Square 
3 398382.550 132794.183 
1 6 100578.400 6286.150 
Diff. Std. Error t-Test 
-393.400 50.144 -7.845 
-173.000 50.144 -3.450 
-239.400 50.144 -4.774 
220.400 50.144 4.395 
154.000 50.144 3.071 











































Condition * Subject 



































































F-Value P-Value G-G H-F 















































#2 #3 #4 #5 #6 #7 #8 
-1.00 2.00 1.00 -6.00 -5.00 -5.00 -5.00 
-8.00 -4.00 -5.00 -7.00 -7.00 -11.0 -7.00 
-4.00 -4.00 -3.00 -6.00 -5.00 -9.00 -6.00 
-6.00 -6.00 -6.00 -7.00 -7.00 -10.0 -8.00 
-3.00 -4.00 0.00 -7.00 -4.00 -8.00 -7.00 
Mean Std. Dev. Std. Error 
-3.000 3.162 1 .118 
-7.125 2.100 .743 
-5.500 1.927 .681 
-7 .250 1.389 .491 
-5.000 2.726 .964 
di Sum of Squares Mean Square F-Value P-Value G-G H-F 
7 145.775 20.825 
4 97.400 24.350 14.631 .0001 .0002 .0001 
28 46.600 1.664 
Diff. Std. Error t-Test P-Value 
4.125 .645 6.395 .0001 
2.500 .645 3.876 .0006 
4.250 .645 6.589 .0001 
2.000 .645 3.101 .0044 
-1.625 .645 -2.519 .0177 
.125 .645 .194 .8477 
-2.125 .645 -3.294 .0027 
1.750 .645 2.713 .0113 
-.500 .645 -. 775 .4447 
-2.250 .645 -3.488 .0016 
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#2 #3 #4 #5 #6 #7 #8 
204.0 222.0 55.00 88.00 142.0 149.0 125.0 
136.0 165.0 50.00 82.00 129.0 146.0 100.0 
154.0 170.0 53.00 103.0 154.0 145.0 113.0 
138.0 175.0 47.00 105.0 137.0 130.0 113.0 
Mean Std. Dev. Std. Error 
166.750 91.819 32.463 
129.875 55.192 19.513 
141.500 54.728 19.349 
133.375 51 .149 18.084 
142.375 54.555 19.288 
di Sum of Squares Mean Square F-Value P-Value G-G H-F 
7 128017.375 18288.196 
4 6650.850 1662.712 3.744 .0146 .0808 .0740 
28 12434. 750 444.098 
Diff. Std. Error t-Test P-Value 
36.875 10.537 3.500 .0016 
25.250 10.537 2.396 .0235 
33.375 10.537 3.167 .0037 
24.375 10.537 2.313 .0283 
-11.625 10.537 -1. 1 03 .2793 
-3.500 10.537 -.332 .7422 
-12.500 10.537 -1. 1 86 .2455 
8.125 10.537 .771 .4471 
-.875 10.537 -.083 .9344 
-9.000 10.537 -.854 .4003 
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